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Abstract
The eld of survival analysis has experienced tremendous growth during the latter half of
the 20th century. The methodological developments of survival analysis that have had the
most profound impact are the Kaplan-Meier method for estimating the survival function,
the log-rank test for comparing the equality of two or more survival distributions, and the
Cox proportional hazards (PH) model for examining the covariate e¤ects on the hazard
function. The accelerated failure time (AFT) model was proposed but seldom used. In this
thesis, we present the basic concepts, nonparametric methods (the Kaplan-Meier method
and the log-rank test), semiparametric methods (the Cox PH model, and Cox model with
time-dependent covariates) and parametric methods (Parametric PH model and the AFT
model) for analyzing survival data.
We apply these methods to a randomized placebo-controlled trial to prevent Tuberculosis
(TB) in Ugandan adults infected with Human Immunodiciency Virus (HIV). The ob-
jective of the analysis is to determine whether TB preventive therapies a¤ect the rate of
AIDS progression and survival in HIV-infected adults. Our conclusion is that TB preven-
tive therapies appear to have no e¤ect on AIDS progression, death and combined event of
AIDS progression and death. The major goal of this paper is to support an argument for
the consideration of the AFT model as an alternative to the PH model in the analysis of
some survival data by means of this real dataset. We critique the PH model and assess
the lack of t. To overcome the violation of proportional hazards, we use the Cox model
with time-dependent covariates, the piecewise exponential model and the accelerated fail-
ure time model. After comparison of all the models and the assessment of goodness-of-t,
we nd that the log-logistic AFT model ts better for this data set. We have seen that
the AFT model is a more valuable and realistic alternative to the PH model in some situa-
tions. It can provide the predicted hazard functions, predicted survival functions, median
survival times and time ratios. The AFT model can easily interpret the results into the
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e¤ect upon the expected median duration of illness for a patient in a clinical setting. We
suggest that the PH model may not be appropriate in some situations and that the AFT
model could provide a more appropriate description of the data.
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Chapter 1
Introduction
Survival analysis is a statistical method for data analysis where the outcome variable
of interest is the time to the occurrence of an event [35]. Hence, survival analysis is also
referred to as "time to event analysis", which is applied in a number of applied elds, such
as medicine, public health, social science, and engineering. In medical science, time to event
can be time until recurrence in a cancer study, time to death, or time until infection. In the
social sciences, interest can lie in analyzing time to events such as job changes, marriage,
birth of children and so forth. The engineering sciences have also contributed to the
development of survival analysis which is called failure time analysis since the main focus
is in modelling the lifetimes of machines or electronic components [37]. The developments
from these diverse elds have for the most part been consolidated into the eld of survival
analysis. Because these methods have been adapted by researchers in di¤erent elds, they
also have several di¤erent names: event history analysis (sociology), failure time analysis
(engineering), duration analysis or transition analysis (economics). These di¤erent names
do not imply any real di¤erence in techniques, although di¤erent disciplines may emphasize
slightly di¤erent approaches. Survival analysis is the name that is most widely used and
recognized [38].
The complexities provided by the presence of censored observations led to the devel-
opment of a new eld of statistical methodology. The methodological developments in
survival analysis were largely achieved in the latter half of the 20th century. Although
Bayesian methods in survival analysis [26] are well developed and are becoming quite com-
mon for survival data, our application will focus on frequentist methods. There have been
several textbooks written that address survival analysis from a frequentist perspective.
These include Lawless [37], Cox and Oakes [14], Fleming and Harrington [18], and Klein
and Moeschberger [34].
One of the oldest and most straightforward non-parametric methods for analyzing
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survival data is to compute the life table, which was proposed by Berkson and Gage
[6] for studying cancer survival. One important development in non-parametric analysis
methods was obtained by Kaplan and Meier [33]. While non-parametric methods work
well for homogeneous samples, they do not determine whether or not certain variables are
related to the survival times. This need leads to the application of regression methods for
analyzing survival data. The standard multiple linear regression model is not well suited
to survival data for several reasons. Firstly, survival times are rarely normally distributed.
Secondly, censored data result in missing values for the dependent variable (survival time)
[35]. The Cox proportional hazards (PH) model is now the most widely used for the
analysis of survival data in the presence of covariates or prognostic factors. This is the
most popular model for survival analysis because of its simplicity, and not being based on
any assumptions about the survival distribution. The model assumes that the underlying
hazard rate is a function of the independent covariates, but no assumptions are made about
the nature or shape of the hazard function. In the last several years, the theoretical basis
for the model has been solidied by connecting it to the study of counting processes and
martingale theory, which was discussed in the books of Fleming and Harrington [18] and
of Andersen et al [2]. These developments have led to the introduction of several new
extensions to the original model. However the Cox PH model may not be appropriate in
many situations and other modications such as stratied Cox model [35] or Cox model
with time-dependent variables [10] can be used for the analysis of survival data. The
accelerated failure time (AFT) [10] model is another alternative method for the analysis
of survival data.
The purpose of this thesis is to compare the performance of the Cox models and the
AFT models. This will be studied by means of real dataset which is from a random-
ized placebo-controlled trial to prevent tuberculosis (TB) in Ugandan adults infected with
human immunodeciency virus (HIV).
The rest of thesis is organized as follows. In the rest of this chapter, we introduce the
main concepts and survival distributions in survival analysis. In Chapter 2, we discuss
Kaplan-Meier survival curves and non-parametric test such as the log-rank test [40]. In
Chapter 3, we start with an introduction of the Cox PH model which is the most popular
regression model in survival analysis. Then we will discuss the estimation and assumptions
in the Cox PH model. Model checking using residuals is also described. At last we describe
2
the methodology when the PH assumption is violated. In Chapter 4, we will describe the
parametric PH model and the AFT model. The main objective of the rst four chapters is
to develop the background of survival analysis that we will apply to our TB/HIV dataset.
In Chapter 5, we rst describe some background knowledge of TB/HIV and the dataset
we will use. Then we t all methods described in the rst four chapters to the dataset and
give the results. At last, we summarize our experience of using the Cox models versus the
AFT models. Chapter 6 provides a summary of the discussion on this study and further
research on the subject is discussed.
1.1 Basic concepts
Before going into details about survival analysis, we discuss the following basic denitions.
The primary concept in survival analysis is survival time which is also called failure time.
Denition 1.1.1 survival time is a length of time that is measured from time origin to
the time the event of interest occurred.
To determine survival time precisely, there are three requirements: A time origin must
be unambiguously dened, a scale for measuring the passage of time must be agreed upon
and nally the denition of event (often called failure) must be entirely clear.
The specic di¢ culties in survival analysis arise largely from the fact that only some
individuals have experienced the event and other individuals have not had the event in the
end of study and thus their actual survival times are unknown. This leads to the concept
of censoring.
Denition 1.1.2 Censoring occurred when we have some information about individual
survival time, but we do not know the survival time exactly.
There are three types of censoring: 1) right censoring, 2) left censoring, and 3) interval
censoring.
Right censoring is said to occur if the event occurs after the observed survival time.
Let C denote the censoring time, that is, the time beyond which the study subject cannot
be observed. The observed survival time is also referred to as follow up time. It starts
at time 0 and continues until the event X or a censoring time C, whichever comes rst.
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The observed data are denoted by (T; ), where T = min (X;C) is the follow-up time, and
 = I(XC) is an indicator for status at the end of follow-up,
 = I(XC) :=
8<: 0 if X > C (observed censoring)1 if X  C (observed failure) :
There are some reasons why right censoring may occur, for example, no event before the
study ends, loss to follow-up during study period, or withdrawal from the study because
of some reasons. The last reason may be caused by competing risks. The right censored
survival time is then less than the actual survival time.
Censoring can also occur if we observe the presence of a condition but do not know
where it began. In this case we call it left censoring, and the actual survival time is less
than the observed censoring time.
If an individual is known to have experienced an event within an interval of time but
the actual survival time is not known, we say we have interval censoring. The actual
occurrence time of event is known within an interval of time.
Right censoring is very common in survival time data, but left censoring is fairly rare.
The term "censoring" will be used in this thesis to mean in all instances "right censoring".
An important assumption for methods presented in this thesis for the analysis of censored
survival data is that the individuals who are censored are at the same risk of subsequent
failure as those who are still alive and uncensored. i.e., a subject whose survival time is
censored at time C must be representative of all other individuals who have survived to
that time. If this is the case, the censoring process is called non-informative. Statistically,
if the censoring process is independent of the survival time, i.e.,
P (X  x;C  x) = P (X  x)P (C  x);
then we will have non-informative censoring. Independence censoring is a special case of
non-informative censoring. In this thesis, we assume that the censoring is non-informative
right censoring.
1.2 Survival time distribution
Let T be a random variable denoting the survival time. The distribution of survival times
is characterized by any of three functions: the survival function, the probability density
function or the hazard function. The following denitions are based on textbook [32].
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Note the survival function is dened for both discrete and continuous T , and the prob-
ability density and hazard functions are easily specied for discrete and continuous T .
Denition 1.2.1 The survival function is dened as the probability that the survival time
is greater or equal to t.
S(t) = P (T  t), t  0:
1.2.1 T discrete
For a discrete random variable T taking well-ordered values 0  t1 < t2 <   , let the
probability mass function be given by P (T = ti) = f(ti), i = 1; 2; :::, then the survival
function is
S(t) =
X
jjtjt
f(tj)
=
X
f(tj)I(tjt);
where the indicator function I(tjt) :=
8<: 0 if tj < t1 if tj  t :
In this case, the hazard function h (t) is dened as the conditional probability of failure
at time tj given that the individual has survived up to time tj ,
hj = h(tj) = P (T = tj jT  tj) = f(tj)
S(tj)
=
S (tj)  S (tj+1)
S (tj)
= 1  S(tj+1)
S(tj)
:
Thus,
1  h(tj) = S(tj+1)
S(tj)
;
and Y
jjtj<t
(1  h(tj)) = S(t2)
S(t1)
 S(t3)
S(t2)
 ::: S(tj+1)
S(tj)
= S(t); (1.1)
because S(t1) = 1 and S(t) = S(tj+1):
Moreover,
f(tj) = h(tj) S(tj)
= h(tj)
j 1Y
i=1
(1  h(ti)): (1.2)
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1.2.2 T absolutely continuous
For an absolutely continuous variable T , The probability density function of T is
f(t) = F
0
(t) =  S0(t); t  0:
Denition 1.2.2 The hazard function gives the instantaneous failure rate at t given that
the individual has survived up to time t, i.e.,
h(t) = lim
t#0
P (t  T < t+tjT  t)
t
; t  0:
There is a clearly dened relationship between S(t) and h(t), which is given by the
formula
h(t) = f(t)=S(t) =
 d logS(t)
dt
, (1.3)
S(t) = exp

 
Z t
0
h(u)du

= exp( H(t)); t  0; (1.4)
where H(t) =
R t
0 h(u)du is called the cumulative hazard function, which can be obtained
from the survival function since H (t) =   logS (t) :
The probability density function of T can be written
f(t) = h(t) exp

 
Z t
0
h(u)du

; t  0:
These three functions give mathematically equivalent specication of the distributions
of the survival time T . If one of them is known, the other two are determined. One of
these functions can be chosen as the basis of statistical analysis according to the particular
situations. The survival function is most useful for comparing the survival progress of two
or more groups. The hazard function gives a more useful description of the risk of failure
at any time point.
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Chapter 2
Non-parametric methods
In survival analysis, it is always a good idea to present numerical or graphical sum-
maries of the survival times for the individuals. In general, survival data are conveniently
summarized through estimates of the survival function and hazard function. The esti-
mation of the survival distribution provides estimates of descriptive statistics such as the
median survival time [10]. These methods are said to be non-parametric methods since
they require no assumptions about the distribution of survival time. In order to compare
the survival distribution of two or more groups, log-rank tests [40] can be used.
2.1 The Kaplan-Meier estimate of the survival function
The life table [6] is the earliest statistical method to study human mortality rigorously, but
its importance has been reduced by the modern methods, like the Kaplan-Meier (K-M)
method [33]. In clinical studies, individual data is usually available on time to death or
time to last seen alive. The K-M estimator for the survival curves is usually used to analyze
individual data, whereas the life table method applies to grouped data. Since the life table
method is a grouped data statistic, it is not as precise as the K-M estimate, which uses
the individual values. We only describe the K-M estimate here.
Suppose that r individuals have failures in a group of individuals. Let 0  t(1) < ::: <
t(r) < 1 be the observed ordered death times. Let rj be the size of the risk set at t(j),
where risk set denotes the collection of individuals alive and uncensored just before t(j).
Let dj be the number of observed deaths at t(j), j = 1; :::; r. Then the K-M estimator of
S (t) is dened by bS(t) = Y
j:t(j)<t
(1  dj
rj
):
This estimator is a step function that changes values only at the time of each death.
In fact, K-M estimator will be shown next to maximize the likelihood in the discrete case
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[14].
Suppose that the distribution is discrete, with atoms hj at nitely many specied points
0  1 < 2 <    < j : As described in Section 1.2, the survival function S(t) may be
expressed in terms of the discrete hazard function hj as
S(t) =
Y
jjj<t
(1  hj):
To derive the full likelihood from a sample of n observations, we rst collect all the
terms corresponding to the atom j . Let bi = j if the ith individual dies at j : Using (1.2),
the contribution to the total log likelihood is
log hbi +
X
k<bi
log(1  hk):
Let ei = j if the ith individual is censored at j ; using the equation (1.1), the log likelihood
contribution to the total likelihood is
X
kei
log(1  hk):
Then the total log likelihood is given by
l =
X
death i
log hbi +
X
death i
24X
k<bi
log(1  hk)
35+ X
censor i
24X
kei
log(1  hk)
35
=
X
j
dj log hj +
X
k
24X dj
j>k
35 log(1  hk) +X
k
24X cj
jk
35 log(1  hk)
=
X
j
[dj log hj + (rj   dj) log(1  hj)];
where dj is the number of observed death at j , cj is the number censored at [j; j+1);
and rj is the number of living and uncensored at j :
If hj is the solution of
@l
@hj
=
dj
hj
  rj   dj
1  hj = 0;
then
bhj = dj=rj :
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This maximizes the likelihood since the total log likelihood function is concave down. So
that the K-M estimator of the survival function is
bS(t) = Y
jjj<t
(1  bhj)
=
Y
jjj<t
(1  dj
rj
):
Therefore, the K-M estimator is the maximum likelihood estimator.
The K-M estimator gives a discrete distribution. If the observations are modelled to
come from unknown continuous distribution, the maximum likelihood estimator does not
exist [27].
2.1.1 Greenwoods formula
Condence intervals for the survival probability can also be calculated by the well known
Greenwoods formula [23].
First, we need the variances of the bhjs. Let the number of individual at risk at t(j) be
rj and the number of deaths at t(j) be dj . Given rj , the number of individuals surviving
through the interval [t(j); t(j+1)); rj   dj , can be assumed to have binomial distribution
with parameters rj and 1  hj : The conditional variance of rj   dj is given by
V (rj   dj jrj) = rjhj(1  hj):
The variance of bhj is
V
bhj jrj = V 1  bhj = V 1  dj
rj

=
hj (1  hj)
rj
:
Since bhj is conditional independent of bh1;...,bhj 1 given r1; :::; rj 1; the delta method
[11] can be used to obtain
V (ln bS(t)jrj : t(j) < t) = V
24 X
j:t(j)<t
(ln(1  bhj))jrj
35
=
X
j:t(j)<t
V
h
ln(1  bhj)jrji

X
j:t(j)<t
(
d
dx
ln(1  x))2
x=bhjV
bhj jrj
=
X
j:t(j)<t
(
  1
1  bhj
)2
hj (1  hj)
rj
; j = 1; :::; r:
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We can estimate this by simply replacing hj with bhj = dj=rj ; which gives
bV ln bS(t) = X
j:t(j)<t
dj
rj (rj   dj) ; j = 1; :::; r:
Let Y = ln bS(t), again using the delta method, we get
bV bS(t)  hbS(t)i2 X
j:t(j)<t
dj
rj (rj   dj) : (2.1)
This is known as Greenwoods formula. The K-M estimator and functions of it have
been proved to be asymptotically normal distributed [2], [18]. Thus the condence intervals
can be constructed by the normal approximation based on S (t).
2.1.2 Estimating the median and percentile of survival time
Since the distribution of survival time tends to be positively skewed, the median is preferred
for a summary measure. The median survival time is the time beyond which 50% of the
individuals under study are expected to survive, i.e., the value of t (50) at bS (t (50)) = 0:5.
The estimated median survival time is given by
bt (50) = minntijbS (ti) < 0:5o ;
where ti is the observed survival time for the ith individual, i = 1; 2; :::; n. In general, the
estimate of the pth percentile is
bt (p) = minntijbS (ti) < 1  p
100
o
:
A condence interval for the percentiles using delta method was discussed in the text-
books [2], [10], The variance of the estimator of the pth percentile is
V [bS (t (p))] =  dbS (t (p))
dt (p)
!2
V ft (p)g
=

  bf (t (p))2 V ft (p)g :
The standard error of bt (p) is therefore given by
SE
bt (p) = 1bf (t (p))SE
hbS  bt (p)i :
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The standard error of bS  bt (p) can be obtained using Greenwoods formula, given in
equation (2.1). An estimate of the probability density function at the pth percentile bt (p)
is used by many software packages
bf bt (p) = bS [bu (p)]  bS
hbl (p)ibl (p)  bu (p) ;
where
bu (p) = maxnt(j)jbS  t(j)  1  p100 + "o ;bl (p) = minnt(j)jbS  t(j)  1  p100   "o ;
t(j) is jth ordered death time, j = 1; 2; :::r: " = 0:05 is typically used by a number of
statistical packages. Therefore, for median survival time, bu (50) is the largest observed
survival time from the K-M curve for which bS (t)  0:55, and bl (50) is the smallest observed
survival time from the K-M curve for which bS (t)  0:45:
The 95% condence interval for the pth percentile bt (p) has limits of
bt (p) 1:96SEfbt (p)g:
2.2 Nonparametric comparison of survival distributions
The K-M survival curves can give us an insight about the di¤erence of survival functions in
two or more groups, but whether this observed di¤erence is statistically signicant requires
a formal statistical test. There are a number of methods that can be used to test equality
of the survival functions in di¤erent groups. One commonly used non-parametric tests for
comparison of two or more survival distributions is the log-rank test [40].
Lets take two groups as an example. Let t(1) < t(2) < ::: < t(k) be the ordered death
times across two groups. Suppose that dj failures occur at t(j) and that rj subjects are
at risk just prior to t(j) (j = 1; 2; :::; k). Let dij and rij be the corresponding numbers in
group i (i = 1; 2).
The log-rank test compares the observed number of deaths with the expected number
of deaths for group i. Consider the null hypothesis: S1(t) = S2(t); i.e. there is no di¤erence
between survival curves in two groups.
Given rj and dj , the random variable d1j has the hypergeometric distribution  dj
d1j
  rj dj
r1j d1j
 
rj
r1j
 :
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Under the null hypothesis, the probability of death at t(j) does not depend on the group,
i.e., the probability of death at t(j) is
dj
rj
. So that the expected number of deaths in group
one is
E(d1j) = e1j = r1jdjr
 1
j :
The test statistic is given by the di¤erence between the total observed and expected
number of deaths in group one
UL =
rX
j=1
(d1j   e1j): (2.2)
Since d1j has the hypergeometric distribution, the variance of d1j is given by
v1j = V (d1j) =
r1jr2jdj (rj   dj)
r2j (rj   1)
: (2.3)
So that the variance of UL is
V (UL) =
rX
j=1
v1j = VL:
Under the null hypothesis, statistic (2.2) has an approximate normal distribution with zero
mean and variance VL. This then follows
U2L
VL
 {21 :
There are several alternatives to the log-rank test to test the equality of survival curves,
for example, the Wilcoxon test [20]. These tests may be dened in general as follows:Pr
j=1wj(d1j   e1j)Pr
j=1w
2
j v1j
;
where wj are weights whose values depend on the specic test.
The Wilcoxon test uses weights equal to risk size at t(j), wj = rj : This gives less weight
to longest survival times. Early failures receive more weight than later failures. The
Wilcoxon test places more emphasis on the information at the beginning of the survival
curve where the number at risk is large. This type of weighting may be used to assess
whether the e¤ect of treatment on survival is strongest in the earlier phases of adminis-
tration and tends to be less e¤ective over time. Whereas the log-rank test uses weights
equal to one at t(j), wj = 1. This gives the same weight to each survival time. Therefore,
Wilcoxon statistic is less sensitive than the log-rank statistic to di¤erence of d1j from e1j
in the tail of the distribution of survival times.
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The log-rank test is appropriate when hazard functions for two groups are proportional
over time, i.e., h1(t) = h2(t): So it is the most likely to detect a di¤erence between groups
when the risk of a failure is consistently greater for one group than another.
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Chapter 3
Cox regression model
3.1 Introduction
The non-parametric method does not control for covariates and it requires categorical pre-
dictors. When we have several prognostic variables, we must use multivariate approaches.
But we cannot use multiple linear regression or logistic regression because they cannot
deal with censored observations. We need another method to model survival data with the
presence of censoring. One very popular model in survival data is the Cox proportional
hazards model, which is proposed by Cox [12].
Denition 3.1.1 The Cox Proportional Hazards model is given by
h(tjx) = h0(t) exp(1x1 + 2x2 + :::+ pxp) = h0(t) exp(0x);
where h0(t) is called the baseline hazard function, which is the hazard function for an
individual for whom all the variables included in the model are zero., x = (x1; x2; :::; xp)
0
is the values of the vector of explanatory variables for a particular individual, and 
0
=
(1; 2; :::; p) is a vector of regression coe¢ cients.
The corresponding survival functions are related as follows:
S(tjx) = S0 (t)
exp(
Pp
i=1
ixi)
:
This model, also known as the Cox regression model, makes no assumptions about the
form of h0(t) (non-parametric part of model) but assumes parametric form for the e¤ect of
the predictors on the hazard (parametric part of model). The model is therefore referred
to as a semi-parametric model.
The beauty of the Cox approach is that this vagueness creates no problems for estima-
tion. Even though the baseline hazard is not specied, we can still get a good estimate for
regression coe¢ cients , hazard ratio, and adjusted hazard curves.
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The measure of e¤ect is called hazard ratio. The hazard ratio of two individuals with
di¤erent covariates x and x is
dHR = h0(t) exp(b0x)
h0(t) exp(b0x) = exp
Xb0(x  x) :
This hazard ratio is time-independent, which is why this is called the proportional hazards
model.
3.2 Partial likelihood estimate for Cox proportional hazards
model
Fitting the Cox proportional hazards model, we wish to estimate h0 (t) and : One ap-
proach is to attempt to maximize the likelihood function for the observed data simultane-
ously with respect to h0 (t) and . A more popular approach is proposed by Cox [13] in
which a partial likelihood function that does not depend on h0 (t) is obtained for : Partial
likelihood is a technique developed to make inference about the regression parameters in
the presence of nuisance parameters (h0 (t) in the Cox PH model). In this section, we will
construct the partial likelihood function based on the proportional hazards model.
Let t1; t2; :::; tn be the observed survival time for n individuals. Let the ordered death
time of r individuals be t(1) < t(2) < ::: < t(r) and let R(t(j)) be the risk set just before t(j)
and rj for its size. So that R(t(j)) is the group of individuals who are alive and uncensored
at a time just prior to t(j). The conditional probability that the ith individual dies at t(j)
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given that one individual from the risk set on R(t(j)) dies at t(j) is
P (individual i dies at t(j)j one death from the risk set R(t(j)) at t(j))
=
P
 
individual i dies at t(j)

P
 
one death at t(j)

=
P
 
individual i dies at t(j)
P
k2R(t(j))
P
 
individual k dies at t(j)

' Pfindividual i dies at (t(j); t(j) +t)g=tP
k2R(t(j))
Pfindividual k dies at (t(j); t(j) +t)g=t
=
limt#0 Pfindividual i dies at (t(j); t(j) +t)g=t
limt#0
P
k2R(t(j))
Pfindividual k dies at (t(j); t(j) +t)g=t
=
hi(t(j))P
k2R(t(j))
hk(t(j))
=
h0(t(j)) exp(
0
xi(t(j))P
k2R(t(j))
h0(t(j)) exp(
0
xk(t(j))
=
exp(
0
xi(t(j))P
k2R(t(j))
exp(
0
xk(t(j))
:
Then the partial likelihood function for the Cox PH model is given by
L () =
rY
j=1
exp(
0
xi(t(j))P
k2R(t(j))
exp(
0
xk(t(j))
; (3.1)
in which xi(t(j)) is the vector of covariate values for individual i who dies at t(j): The
general method of partial likelihood was discussed by Cox [13].
Note that this likelihood function is only for the uncensored individuals. Let t1; t2; :::; tn
be the observed survival time for n individuals and i be the event indicator, which is zero if
the ith survival time is censored, and unity otherwise. The likelihood function in equation
(3.1) can be expressed by
L () =
nY
i=1
264 exp(0xi(ti)P
k2R(ti)
exp(
0
xk(ti)
375
i
; (3.2)
where R(ti) is the risk set at time ti:
The partial likelihood is valid when there are no ties in the dataset. That means there
is no two subjects who have the same event time.
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3.3 Proportional hazard assumption checking
The main assumption of the Cox proportional hazards model is proportional hazards. Pro-
portional hazards means that the hazard function of one individual is proportional to the
hazard function of the other individual, i.e., the hazard ratio is constant over time. There
are several methods for verifying that a model satises the assumption of proportionality.
3.3.1 Graphical method
We can obtain Cox PH survival function by the relationship between hazard function and
survival function
S(t;x) = S0(t)
exp(
Pp
i=1 ixi);
where x = (x1; x2; :::; xp)
0
is the values of the vector of explanatory variables for a particular
individual. When taking the logarithm twice, we can easily get
ln[  lnS(t;x)] =
pX
i=1
ixi + ln[  lnS0 (t)]:
Then the di¤erence in log-log curves corresponding to two di¤erent individuals with
variables x1 = (x11; x12; :::; x1p) and x2 = (x21; x22; :::; x2p) is given by
ln[  lnS(t;x1)]  ln[  lnS(t;x2)] =
pX
i=1
i(x1i   x2i);
which does not depend on t. This relationship is very helpful to help us identify situations
where we may have proportional hazards. By plotting estimated log(  log(survival)) versus
survival time for two groups we would see parallel curves if the hazards are proportional.
This method does not work well for continuous predictors or categorical predictors that
have many levels because the graph becomes "cluttered". Furthermore, the curves are
sparse when there are few time points and it may be di¢ cult to tell how close to parallel
is close enough.
However, looking at the K-M curves and log(  log(survival)) is not enough to be certain
of proportionality since they are univariate analysis and do not show whether hazards will
still be proportional when a model includes many other predictors. But they support our
argument for proportionality. We will show some other statistical methods for checking
the proportionality.
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3.3.2 Adding time-dependent covariates in the Cox model
We create time-dependent covariates by creating interactions of the predictors and a func-
tion of survival time and including them in the model. For example, if the predictor of
interest is Xj , then we create a time-dependent covariate Xj(t), Xj(t) = Xj  g (t) ; where
g (t) is a function of time, e.g., t, log t or Heaviside function of t. The model assessing PH
assumption for Xj adjusted for other covariates is
h(t;x (t)) = h0 (t) exp[1x1 + 2x2 + :::+ jxj + :::+ pxp + xj  g (t)];
where x (t) = (x1; x2; :::; xp; xj (t))
0
is the values of the vector of explanatory variables for
a particular individual. The null hypothesis to check proportionality is that  = 0. The
test statistic can be carried out using either a Wald test or a likelihood ratio test. In the
Wald test, the test statistic is W =
b=seb2 : The likelihood ratio test calculates the
likelihood under null hypothesis, L0 and the likelihood under the alternative hypothesis,
La. The LR statistic is then LR =  2 ln (L0=La) =  2 (l0   la), where l0, la are log
likelihood under two hypothesis respectively. Both statistics have a chi-square distribution
with one degree of freedom under the null hypothesis. If the time-dependent covariate is
signicant, i.e., the null hypothesis is rejected, then the predictor is not proportional. In
the same way, we can also assess the PH assumption for several predictors simultaneously.
3.3.3 Tests based on the Schoenfeld residuals
The other statistical test of the proportional hazards assumption is based on the Schoenfeld
residual [48]. The Schoenfeld residuals are dened for each subject who is observed to fail.
We will talk about it in detail in Section 3.4.2. If the PH assumption holds for a particular
covariate then the Schoenfeld residual for that covariate will not be related to survival time.
So this test is accomplished by nding the correlation between the Schoenfeld residuals for
a particular covariate and the ranking of individual survival times. The null hypothesis is
that the correlation between the Schoenfeld residuals and the ranked survival time is zero.
Rejection of null hypothesis concludes that PH assumption is violated.
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3.4 Cox proportional hazards model diagnostics
After a model has been tted, the adequacy of the tted model needs to be assessed. The
model checking procedures below are based on residuals. In linear regression methods,
residuals are dened as the di¤erence between the observed and predicted values of the
dependent variable. However, when censored observations are present and partial likelihood
function is used in the Cox PH model, the usual concept of residual is not applicable. A
number of residuals have been proposed for use in connection with the Cox PH model. We
will describe three major residuals in the Cox model: the Cox-Snell residual, the deviance
residual, and the Schoenfeld residual. Then we will talk about inuence assessment.
3.4.1 Cox-Snell residuals and deviance residuals
The Cox-Snell residual is given by Cox and Snell [15]. The Cox-Snell residual for the ith
individual with observed survival time ti is dened as
rci = exp
b0xi bH0 (ti) = bHi (ti) =   log bSi (ti) ;
where bH0 (ti) is an estimate of the baseline cumulative hazard function at time ti; which
was derived by Kalbeisch and Prentice [31].
This residual is motivated by the following result: Let T have continuous survival dis-
tribution S(t) with the cumulative hazard H(t) =   log(S(t)). Thus, ST (t) = exp( H(t)).
Let Y = H(T ) be the transformation of T based on the cumulative hazard function. Then
the survival function for Y is
SY (y) = P (Y > y) = P (H(t) > y)
= P (T > H 1T (y)) = ST (H
 1
T (y))
= exp( HT (H 1T (y))) = exp( y):
Thus, regardless of the distribution of T , the new variable Y = H(T ) has an exponential
distribution with unit mean. If the model was well tted, the value bSi (ti) would have
similar properties to those of Si (ti) : So rci =   log bSi (ti) will have a unit exponential
distribution with fR (r) = exp ( r). Let SR (r) denote the survival function of Cox-Snell
residual rci . Then
SR (r) =
Z 1
r
fR (x) dx =
Z 1
r
exp ( x) dx = exp ( r) ;
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and
HR (r) =   logSR (r) =   log (exp ( r)) = r:
Therefore, we use a plot of H(rci) versus rci to check the t of the model. This gives a
straight line with unit slope and zero intercept if the tted model is correct. Note the Cox-
Snell residuals will not be symmetrically distributed about zero and cannot be negative.
The deviance residual [53] is dened by
rDi = sign(rmi)[ 2frmi + i log(i   rmig]1=2;
where the function sign(:) is the sign function which takes the value 1 if rmi is positive
and -1 if rmi is negative; rmi = i  rci is the martingale residuals [5] for the ith individual;
and i = 1 for uncensored observation, i = 0 for censored observation.
The martingale residuals take values between negative innity and unity. They have a
skewed distribution with mean zero [3]. The deviance residuals are a normalized transform
of the martingale residuals [53]. They also have a mean of zero but are approximately sym-
metrically distributed about zero when the tted model is appropriate. Deviance residual
can also be used like residuals from linear regression. The plot of the deviance residuals
against the covariates can be obtained. Any unusual patterns may suggest features of the
data that have not been adequately tted for the model. Very large or very small values
suggest that the observation may be an outlier in need of special attention. In a tted Cox
PH model, the hazard of death for the ith individual at any time depends on the value of
exp(
0
xi) which is called the risk score. A plot of the deviance residuals versus the risk
score is a helpful diagnostic to assess a given individual on the model. Potential outliers
will have deviance residuals whose absolute values are very large. This plot will give the
information about the characteristic of observations that are not well tted by the model.
3.4.2 Schoenfeld residuals
All the above three residuals are residuals for each individual. We will describe covariate-
wise residuals: Schoenfeld residuals [48]. The Schoenfeld residuals were originally called
partial residuals because the Schoenfeld residuals for ith individual on the jth explanatory
variable Xj is an estimate of the ith component of the rst derivative of the logarithm of
the partial likelihood function with respect to j : From equation (3.2), this logarithm of
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the partial likelihood function is given by
@ logL()
@j
=
pX
i=1
i fxij   aijg ;
where xij is the value of the jth explanatory variable j = 1; 2; :::; p for the ith individual
and
aji =
P
l2R(ti) xjl exp(
0
xl)P
l2R(ti) exp(
0
xl)
:
The Schoenfeld residual for ith individual on Xj is given by rpji = i fxji   ajig : The
Schoenfeld residuals sum to zero.
3.4.3 Diagnostics for inuential observations
Observations that have an undue e¤ect on model-based inference are said to be inuential.
In the assessment of model adequacy, it is important to determine whether there are any
inuential observations. The most direct measure of inuence is bj   bj(i), where bj is the
jth parameter, j = 1; 2; :::; p in a tted Cox PH model and bj(i) is obtained by tting the
model after omitting observation i. In this way, we have to t the n+ 1 Cox models, one
with the complete data and n with each observation eliminated. This procedure involves
a signicant amount of computation if the sample size is large. We would like to use an
alternative approximate value that does not involve an iterative retting of the model. To
check the inuence of observations on a parameter estimate, Cain and Lange [9] showed
that an approximation to bj   bj(i) is the jth component of the vector
r
0
SiV (
b);
where rSi is the p  1 vector of score residuals for the ith observation [10], which are
modications of Schoenfeld residuals and are dened for all the observations, and V (b) is
the variance-covariance matrix of the vector of parameter estimates in the tted Cox PH
model. The jth element of this vector is called delta-beta statistic for the jth explanatory
variable, i.e., ibj  bj   bj(i); which tells us how much each coe¢ cient will change by
removal of a single observation. Therefore, we can check whether there are inuential
observations for any particular explanatory variable.
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3.5 Strategies for analysis of nonproportional data
Suppose that statistic tests or other diagnostic techniques give strong evidence of nonpro-
portionality for one or more covariates. To deal with this we will describe two popular
methods: stratied Cox model and Cox regression model with time-dependent variables
which are particularly simple and can be done using available software. Another way to
consider is to use a di¤erent model. A parametric model such as an AFT model, which we
will describe in Chapter 4, might be more appropriate for the data.
3.5.1 Stratied Cox model
One method that we can use is the stratied Cox model, which straties on the predictors
not satisfying the PH assumption. The data are stratied into subgroups and the model
is applied for each stratum. The model is given by
hig (t) = hog (t) exp


0
xig

;
where g represents the stratum.
Note that the hazards are non-proportional because the baseline hazards may be dif-
ferent between strata. The coe¢ cients  are assumed to be the same for each stratum
g. The partial likelihood function is simply the product of the partial likelihoods in each
stratum. A drawback of this approach is that we cannot identify the e¤ect of this stratied
predictor. This technique is most useful when the covariate with non-proportionality is
categorical and not of direct interest.
3.5.2 Cox regression model with time-dependent variables
Until now we have assumed that the values of all covariates did not change over the
period of observation. However, the values of covariates may change over time t. Such a
covariate is called a time-dependent covariate. The second method to consider is to model
nonproportionality by time-dependent covariates. The violation of PH assumptions are
equivalent to interactions between covariates and time. That is, the PH model assumes that
the e¤ect of each covariate is the same at all points in time. If the e¤ect of a variable varies
with time, the PH assumption is violated for that variable. To model a time-dependent
e¤ect, one can create a time-dependent covariate X(t), then X(t) = X  g (t). g(t) is
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a function of t such as t; log t or Heaviside functions, etc. The choice of time-dependent
covariates may be based on theoretical considerations and strong clinical evidence.
The Cox regression with both time independent predictors Xi and time-dependent
covariates Xj(t) can be written
h(tjx(t)) = h0(t) exp
24 p1X
i=1
ixi +
p2X
j=1
jxj(t)
35 :
The hazard ratio at time t for the two individuals with di¤erent covariates x and x is
given by
dHR (t) = exp
24 p1X
i=1
bi(xi   xi) + p2X
j=1
bj  xj (t)  xj(t)
35 :
Note that, in this hazard ratio formula, the coe¢ cient bj is not time-dependent. bj
represents overall e¤ect of Xj(t) considering all times at which this variable has been
measured in this study. But the hazard ratio depends on time t. This means that the
hazards of event at time t is no longer proportional, and the model is no longer a PH
model.
In addition to considering time-dependent variable for analyzing a time-independent
variable not satisfying the PH assumption, there are variables that are inherently dened
as time-dependent variables. One of the earliest applications of the use of time-dependent
covariates is in the report by Crowley and Hu [16] on the Stanford Heart Transplant
study. Time-dependent variables are usually classied to be internal or external. An
internal time-dependent variable is one that the change of covariate over time is related
to the characteristics or behavior of the individual. For example, blood pressure, disease
complications, etc. The external time-dependent variable is one whose value at a particular
time does not require subjects to be under direct observations, i.e., values changes because
of external characteristics to the individuals. For example, level of air pollution.
23
Chapter 4
Parametric model
The Cox PH model described in Chapter 3 is the most common way of analyzing
prognostic factors in clinical data. This is probably due to the fact that this model allows
us to estimate and make inference about the parameters without assuming any distribution
for the survival time. However, when the proportional hazards assumption is not tenable,
these models will not be suitable. In this section, we will introduce parametric model, in
which specic probability distribution is assumed for the survival times. In Section 4.1,
we will introduce the parametric proportional hazards (PH) model. In Section 4.2, we
will present the accelerated failure time (AFT) model and more detailed discussions of
exponential, Weibull, log-logistic, log-Normal and gamma AFT models.
4.1 Parametric proportional hazards model
The parametric proportional hazards model is the parametric versions of the Cox propor-
tional hazards model. It is given with the similar form to the Cox PH models. The hazard
function at time t for the particular patient with a set of p covariates (x1; x2:::xp) is given
as follows:
h(tjx) = h0(t) exp(1x1 + 2x2 + :::+ pxp) = h0(t) exp(0x):
The key di¤erence between the two kinds of models is that the baseline hazard function
is assumed to follow a specic distribution when a fully parametric PH model is tted to
the data, whereas the Cox model has no such constraint. The coe¢ cients are estimated by
partial likelihood in Cox model but maximum likelihood in parametric PH model. Other
than this, the two types of models are equivalent. Hazard ratios have the same interpre-
tation and proportionality of hazards is still assumed. A number of di¤erent parametric
PH models may be derived by choosing di¤erent hazard functions. The commonly applied
models are exponential, Weibull, or Gompertz models.
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4.1.1 Weibull PH model
Suppose that survival times are assumed to have a Weibull distribution with scale parame-
ter  and shape parameter , so the survival and hazard function of a W (; ) distribution
are given by
S(t) = exp( t); h(t) = (t) 1;
with ,  > 0. The hazard rate increases when  > 1 and decreases when  < 1 as time
goes on. When  = 1, the hazard rate remains constant, which is the special exponential
case.
Under the Weibull PH model, the hazard function of a particular patient with covariates
(x1; x2; :::; xp) is given by
h(tjx) = (t) 1 exp(1x1 + 2x2 + :::+ pxp) = (t) 1 exp(0x):
We can see that the survival time of this patient has the Weibull distribution with scale
parameter  exp(
0
x) and shape parameter : Therefore the Weibull family with xed 
possesses PH property. This shows that the e¤ects of the explanatory variables in the
model alter the scale parameter of the distribution, while the shape parameter remains
constant.
From equation (1.4), the corresponding survival function is given by
S (tjx) = expf  exp(0x)tg: (4.1)
After a transformation of the survival function for a Weibull distribution, we can obtain
logf  logS(t)g = log +  log t:
The logf  logS(t)g versus log(t) should give approximately a straight line if the Weibull
distribution assumption is reasonable. The intercept and slope of the line will be rough
estimate of log  and  respectively. If the two lines for two groups in this plot are essentially
parallel, this means that the proportional hazards model is valid. Furthermore, if the
straight line has a slope nearly one, the simpler exponential distribution is reasonable.
In the other way, for a exponential distribution, there is logS(t) =  t. Thus we can
consider the graph of logS(t) versus t. This should be a line that goes through the origin
if exponential distribution is appropriate.
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Another approach to assess the suitability of a parametric model is to estimate the
hazard function using the non-parametric method. If the hazard function were reason-
ably constant over time, this would indicate that the exponential distribution might be
appropriate. If the hazard function increased or decreased monotonically with increasing
survival time, a Weibull distribution or Gompertz distribution might be considered.
4.1.2 Exponential PH model
The exponential PH model is a special case of the Weibull model when  = 1. The hazard
function under this model is to assume that it is constant over time. The survival and
hazard function are written as
S(t) = exp( t); h(t) = :
Under the exponential PH model, the hazard function of a particular patient is given
by
h(tjx) =  exp(1x1 + 2x2 + :::+ pxp) =  exp(0x):
The piecewise exponential model [7] is an extension of the exponential PH model. For
the piecewise exponential model, the period of follow-up is divided into k intervals (tj ; tj+1],
j = 1; 2:::k; t1 = 0: Assume that the baseline hazard is constant within each interval but
can vary across intervals, so that h0 (t) = exp(j) = j for tj < t  tj+1; i.e., the baseline
hazard function is approximated by a step function.
The piecewise exponential model is given by
ij = j exp(
0
xi);
where ij is the hazard corresponding to individual i in interval j and exp(
0
xi) is the
relative risk for an individual with covariate value xi compared to the baseline at any given
time.
In the piecewise exponential approach, a log-linear model is used to model both the
e¤ects of the covariates and the underlying hazard function. Estimates of the underlying
hazard function and the regression parameters can be obtained using maximum likelihood.
The maximum likelihood estimate of the baseline hazard function in interval i for given
regression coe¢ cients  is given by
bj = djP
i2Rj
exp(
0
xi)tij
;
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where dj is the number of events in interval j; Rj is the risk set entering interval j, and tij
is the observed survival time for individual i in interval j. This approach was rst studied
by Holford [24], and is also the subject of work by Holford [25] and Laird and Olivier [36].
One of the greatest challenge related to the use of the piecewise exponential model is
to nd an adequate grid of time-points needed in its construction. One of the advantage
of this method is the ability to incorporate time-dependent covariates. If there were any
time-dependent covariates, their values at the beginning of each interval could be assigned
to the records for that time interval.
4.1.3 Gompertz PH model
The survival and hazard function of the Gompertz distribution are given by
S (t) = exp



(1  et

; h (t) =  exp(t);
for 0  t < 1 and  > 0. The parameter  determines the shape of the hazard function.
When  = 0, the survival time then have an exponential distribution, i.e., the exponential
distribution is also a special case of the Gompertz distribution. Like the Weibull hazard
function, the Gompertz hazard increases or decreases monotonically. For the Gompertz
distribution, log(h(t)) is linear with t.
Under the Gompertz PH model, the hazard function of a particular patient is given by
h(tjx) =  exp(t) exp(1x1 + 2x2 + :::+ pxp) =  exp(0x) exp(t):
It is straightforward to see that the Gompertz distribution has the PH property. But the
Gompertz PH model is rarely used in practice.
Most computer software for tting the exponential and Weibull models uses a di¤erent
form of the model, AFT model, which we will describe it in the next section.
4.2 Accelerated failure time model
4.2.1 Introduction
Although parametric PH models are very applicable to analyze survival data, there are
relatively few probability distribution for the survival time that can be used with these
models. In these situations, the accelerated failure time model (AFT) is an alternative
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to the PH model for the analysis of survival time data. Under AFT models we measure
the direct e¤ect of the explanatory variables on the survival time instead of hazard, as we
do in the PH model. This characteristic allows for an easier interpretation of the results
because the parameters measure the e¤ect of the correspondent covariate on the mean
survival time. Currently, the AFT model is not commonly used for the analysis of clinical
trial data, although it is fairly common in the eld of manufacturing. Similar to the PH
model, the AFT model describes the relationship between survival probabilities and a set
of covariates.
Denition 4.2.1 For a group of patients with covariate (X1; X2; :::; Xp) , the model is
written mathematically as S(tjx) = S0(t=(x)), where S0(t) is the baseline survival function
and  is an acceleration factor that is a ratio of survival times corresponding to any
xed value of S(t). The acceleration factor is given according to the formula (x) =
exp(1x1 + 2x2 + :::+ pxp):
Under an accelerated failure time model, the covariate e¤ects are assumed to be con-
stant and multiplicative on the time scale, that is, the covariate impacts on survival by a
constant factor (acceleration factor).
According to the relationship of survival function and hazard function, the hazard
function for an individual with covariate X1; X2; :::; Xp is given by
h(tjx) = [1=(x)]h0[t=(x)]: (4.2)
The corresponding log-linear form of the AFT model with respect to time is given by
log Ti = + 1X1i + 2X2i + :::+ pXpi + "i;
where  is intercept,  is scale parameter and "i is a random variable, assumed to have a
particular distribution. This form of the model is adopted by most software package for
the AFT model.
For each distribution of "i, there is a corresponding distribution for T . The members
of the AFT model class include the exponential AFT model, Weibull AFT model, log-
logistic AFT model, log-normal AFT model, and gamma AFT model. The AFT models
are discussed in details in textbooks [10], [14], [37]. The AFT models are named for the
distribution of T rather than the distribution of "i or log T .
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Distribution of ε Distribution of T
Extreme value(1 parameters) Exponential
Extreme value(2 parameters) Weibull
Logistic Log-logistic
Normal Log-normal
Log-Gamma Gamma
Table 4.1: Summary of parametric AFT models
Parametric
PO modelParametric
PH model
AFT model
Gompetz
Exponential
Weibull
Log-normal
Gamma
Log-logistic
Figure 4.1: Summary of parametric models
The survival function of Ti can be expressed by the survival function of "i :
Si(t) = P (Ti  t)
= P (log Ti  log t)
= P (+ 1x1i + 2x2i + :::+ pxpi + "i  log t)
= P

"i  log t    x


= S"i

log t    x


: (4.3)
The distributions of "i and the corresponding distributions of Ti are summarized in
Table (4.1). And the summary of the commonly used parametric models are described in
Figure (4.1).
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The e¤ect size for the AFT model is the time ratio. The time ratio comparing two levels
of covariate xi (xi = 1 vs. xi = 0) ; after controlling all the other covariates is exp(i),
which is interpreted as the estimated ratio of the expected survival times for two groups.
A time ratio above 1 for the covariate implies that this covariate prolongs the time to
event, while a time ratio below 1 indicates that an earlier event is more likely. Therefore,
the AFT models can be interpreted in terms of the speed of progression of a disease. The
e¤ect of the covariates in an accelerated failure time model is to change the scale, and not
the location of a baseline distribution of survival times.
4.2.2 Estimation of AFT model
AFT models are tted using the maximum likelihood method. The likelihood of the n
observed survival times, t1;t2;:::tn is given by
L(; ; ) =
nY
i=1
ffi(ti)gifSi(ti)g1 i ;
where fi(ti) and Si(ti) are the density and survival functions for the ith individual at ti and
i is the event indicator for the ith observation. Using equation (4.3), the log-likelihood
function is then given by
logL(; ; ) =
nX
i=1
f i log(ti + i log f"i(zi) + (1  i) logS"i(zi))g;
where zi = (log ti     1x1i   2x2i   :::  pxpi)=: The maximum likelihood estimates
of the p+2 unknown parameters, ; ; 1; 2; :::; p; are found by maximizing this function
using the Newton-Raphson procedure in SAS, which is the same method used to maximize
the partial likelihood in the Cox regression model.
Several other approaches have been proposed for the estimation and inference on the
AFT model in the literature. Classical semi-parametric approaches to the AFT model
that emphasize estimation of the regression parameters include the method of Buckley
and James [8] and linear-rank-test-based estimators [32]. Despite theoretical advances, all
these approaches are numerically complicated and di¢ cult to implement, especially when
the number of covariates is large.
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4.2.3 Weibull AFT model
Suppose the survival time T has W (; ) distribution with scale parameter  and shape
parameter : From equation (4.2), under AFT model, the hazard function for the ith
individual is
hi(t) = [1=i (x)]h0[t=i(x)]
= [1=i(x)](t=i(x))
 1
= 1=[i(x)]
(t) 1;
where i = exp(1x1i + 2x2i + ::: + pxpi) for individual i with p explanatory variables.
So the survival time for the ith patient is W (1=[i(x)]; ). The Weibull distribution has
the AFT property.
If Ti has a Weibull distribution, then "i has an extreme value distribution (Gumbel
distribution). The survival function of Gumbel distribution is given by
S"i (") = exp (  exp (")) :
From equation (4.3), the AFT representation of the survival function of the Weibull model
is given by
Si(t) = exp

  exp(log t    1x1i   :::  pxpi)

)

= exp

  exp
   1x1i   :::  pxpi)


t1=

: (4.4)
From equation (4.1), the PH representation of the survival function of the Weibull model
is given by
Si(t) = expf  exp(1x1i + :::+ pxpi)tg: (4.5)
Comparing the above two formulas (4.4) and (4.5), we can easily see that the parameter
; ; j in the PH model can be expressed by the parameters ; ; j in the AFT model:
 = exp( =);  = 1=; j =  j=: (4.6)
Using equation (1.3), the AFT representation of hazard function of the Weibull model
is given by
hi (t) =
1

t
1

 1 exp
   1x1i   :::  pxpi)


: (4.7)
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Suppose the pth percentile of the survival distribution for the ith individual is ti (p) ;
which is the value such that Si (ti (p)) =
100 p
100 : From equation (4.4), we can easily get
ti (p) = exp

 log

  log

100  p
100

+ + 
0
xi

:
The median survival time is
ti (50) = exp
h
 log(log 2) + + 
0
xi
i
: (4.8)
To calculate the standard error of bj , we can use the approximate variance of a function
of two parameter estimate 1, 2; which is given by
@g
@b1
2
V
b1+  @g
@b2
2
V
b2+ 2 @g
@b1 @g@b2

Cov(1; 2):
The approximate variance of bj is expressed as
V (j) =
 1b
2
V (bj) + bjb2
2
V (b) + 2 1b
bjb2

Cov (bj ; b) :
The square root of this is the standard error of bj : Then the 95% condence interval can
be calculated.
4.2.4 Log-logistic AFT model
One limitation of the Weibull hazard function is that it is a monotonic function of time.
However, the hazard function can change direction in some situations. We will describe the
log-logistic model in this section. The log-logistic survival and hazard function are given
by
S(t) =
1
1 + etk
; h(t) =
etk 1
1 + etk
;
where  and k are unknown parameters and k > 0. When k  1, the hazard rate decreases
monotonically and when k > 1, it increases from zero to a maximum and then decreases
to zero.
Suppose that the survival times have a log-logistic distribution with parameter  and k,
then from equation (4.2), under the AFT model, the hazard function for the ith individual
is
hi(t) = (1=i)h0(t=i)
=
e(t=i)
k 1
i(1 + e(t=i))
=
e  log itk 1
1 + e  log itk
;
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where i = exp (1x1 + 2x2 + :::+ pxp) for individual i with p explanatory variables.
Therefore, the survival time for the ith individual has a log-logistic distribution with pa-
rameter    k log i and k; log-logistic distribution has AFT property.
If the baseline survival function is S0(t) = f1 + etkg 1, where  and k are unknown
parameters, then the baseline odds of surviving beyond time t are given by
S0(t)
1  S0(t) = e
 t k:
The survival time for the ith individual also has a log-logistic distribution, which is
Si (t) =
1
1 + e k log itk
: (4.9)
Therefore, the odds of the ith individual surviving beyond time t is given by
Si(t)
1  Si(t) = e
log i t k: (4.10)
We can see that the log-logistic distribution has the proportional odds (PO) property. So
this model is also a proportional odds model, in which the odds of an individual surviving
beyond time t are expressed as
Si(t)
1  Si(t) = exp (1x1i + :::+ pxpi)
S0(t)
1  S0(t) :
In a two group study, using (4.10), the log (odds) of the ith individual surviving beyond
time t are
log

Si(t)
1  Si(t)

= xi      k log t;
where xi is the value of a categorical variable which takes the value one in one group and
zero in the other group. A plot of log [(1  S(t))=S(t)] versus log t should be linear if log-
logistic distribution is appropriate. Therefore we can check the suitability of log-logistic
distribution using the PO property.
If Ti has a log-logistic distribution, then "i has a logistic distribution. The survival
function of logistic distribution is given by
S"i (") =
1
1 + exp (")
:
Using equation (4.3), the AFT representation of survival function of the log-logistic model
is given by
Si (t) =

1 + t1= exp
   1x1i   :::  pxpi

 1
: (4.11)
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Comparing the formula (4.9) and (4.11), we can easily nd a  =  =; k =  1:
According to the relationship of survival and hazard function, the hazard function for
the ith individual is given by
hi (t) =
1
t

1 + t 1= exp

+ 1x1i + :::+ pxpi

 1
: (4.12)
The pth percentile of the survival distribution for the ith individual is ti (p), from
equation (4.11), is
ti (p) = exp

 log

100  p
100

+ +
0
xi

:
The median survival time is
ti (50) = exp(+
0
xi): (4.13)
4.2.5 Log-normal AFT model
If the survival times are assumed to have a log-normal distribution, the baseline survival
function and hazard function are given by
S0(t) = 1  

log t  


; h0 (t) =


log t


h
1  

log t

i
t
;
where  and  are parameters,  (x) is the probability density function and  (x) is the
cumulative density function of the standard normal distribution. The survival function for
the ith individual is
Si(t) = S0 (t=i)
= 1  
 
log t 0xi   

!
;
where i = exp (1x1 + 2x2 + :::+ pxp) : Therefor the log survival time for the ith indi-
vidual has normal (+
0
xi; ): The log-normal distribution has the AFT property.
In a two group study, we can easily get
 1[1  S(t)] = 1=

log t 0xi   

;
where xi is the value of a categorical variable which takes the value one in one group and
zero in the other group. This implies that a plot of  1[1 S(t)] versus log t will be linear
if the log-normal distribution is appropriate.
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4.2.6 Gamma AFT model
There are two di¤erent gamma models discussed in survival analysis literature. The stan-
dard (2-parameter) and the generalized (3-parameter) gamma model. The gamma model
means the generalized gamma model in this thesis. The probability density function of the
generalized gamma distribution with three parameters, ;  and  is dened by
f (t) =

  ()
t 1 exp [  (t)a] t > 0;  > 0;  > 0;  > 0;
where  is the shape parameter of the distribution. The survival function and the hazard
function do not have a closed form for the generalized gamma distribution. The exponen-
tial, Weibull and log-normal models are all special cases of the generalized gamma model.
It is easily to seen that this generalized gamma distribution becomes the exponential dis-
tribution if  =  = 1; the Weibull distribution if  = 1; and the log-normal distribution
if  ! 1: The generalized gamma model can take on a wide variety of shapes except for
any of the special cases. For example, it can have a hazard function with U or bathtub
shapes in which the hazard declines reaches a minimum and then increases.
4.2.7 Model checking
The graphical methods can be used to check if a parametric distribution ts the ob-
served data. Specically, if the survival time follows an exponential distribution, a plot
of log[  logS(t)] versus log t should yield a straight line with slope of 1. If the plots are
parallel but not straight then PH assumption holds but not the Weibull. If the lines for
two groups are straight but not parallel, the Weibull assumption is supported but the PH
and AFT assumptions are violated. The log-logistic assumption can be graphically evalu-
ated by plotting log[(1  S(t))=S(t)] versus log t. If the distribution of survival function is
log-logistic, then the resulting plot should be a straight line. For the log-normal distribu-
tion, a plot of  1[1  S(t)] versus log t should be linear. All these plots are based on the
assumption that the sample is drawn from a homogeneous population, implying that no
covariates are taken into account. So this graphical method is not very reliable in practice.
There are other methods to check the tness of the model.
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Using quantile-quantile plot
An initial method for assessing the potential for an AFT model is to produce a quantile-
quantile plot. For any value of p in the interval (0; 100), the pth percentile is
t(p) = S 1

100 p
100

:
Let t0(p) and t1(p) be the pth percentiles estimated from the survival functions of the
two groups of survival data. The percentiles for the two groups may be expressed as
t0(p) = S
 1
0

100 p
100

; t1(p) = S
 1
1

100 p
100

;
where S0(t) and S1(t) are the survival functions for the two groups. So we can get
S1[t1(p)] = S0[t0(p)]:
Under the AFT model, S1(t) = S0(t=), and so
S1[t1(p)] = S0[t1(p)=]:
Therefore, we get
t0(p) = 
 1t1(p):
The percentiles of the survival distributions for two groups can be estimated by the K-
M estimates of the respective survival functions. A plot of percentiles of the K-M estimated
survival function from one group against another should give an approximate straight line
through the origin if the accelerated failure time model is appropriate. The slope of this
line will be an estimate of the acceleration factor  1:
Using statistical criteria
We can use statistical tests or statistical criteria to compare all these AFT models. Nested
models can be compared using the likelihood ratio test. The exponential model, the Weibull
model and log-normal model are nested within gamma model. For comparing models that
are not nested, the Akaike information criterion (AIC) can be used instead, which is dened
as
AIC =  2l + 2(k + c);
where l is the log-likelihood, k is the number of covariates in the model and c is the
number of model-specic ancillary parameters. The addition of 2(k+ c) can be thought of
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as a penalty if nonpredictive parameters are added to the model. Lower values of the AIC
suggest a better model. But there is a di¢ culty in using the AIC in that there are no formal
statistical tests to compare di¤erent AIC values. When two models have very similar AIC
values, the choice of model may be hard and external model checking or previous results
may be required to judge the relative plausibility of the models rather than relying on AIC
values alone.
Using residual plots
Residual plots can be used to check the goodness of t of the model. Procedures based on
residuals in the AFT model are particularly relevant with the Cox PH model. One of the
most useful plots is based on comparing the distribution of the Cox-Snell residuals with the
unit exponential distribution. The Cox-Snell residual for the ith individual with observed
time ti is dened as
rci =
bH (tijxi) =   log hbS (tijxi)i ;
where ti is the observed survival time for individual i, xi is the vector of covariate values
for individual i, and bS(ti) is the estimated survival function on the tted model. From
equation (4.3), the estimated survival function for the ith individual is given by
bSi (t) = S"i  log t  b  bxib

;
where b; b and b are the maximum likelihood estimator of ;  and  respectively, S"i (")
is the survival function of "i in the AFT model, and
log t b bxib = rsi is referred to as
standardized residual.
The Cox-Snell residual can be applied to any parametric model. The corresponding
form of residual based particular AFT model can be obtained. For example, under the
Weibull AFT model, since S"i (") = exp ( e"), the Cox-Snell residual is then
rci =   logfbS (ti)g =   logS"i (rsi) = exp (rsi) :
Under the log-logistic AFT model, since S"i (") = (1+e
") 1; the Cox-Snell residual is then
rci = log[1 + exp (rsi)]:
If the tted model is appropriate, the plot of log(  logS(rci)) versus log rci is a straight
line with unit slope through the origin.
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These residuals lead to the deviance residuals for the particular AFT model. A plot of
deviance residuals against the survival time or explanatory variables can be used to check
whether there are particular times, or particular values of explanatory variables, for which
the model is not a good t.
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Chapter 5
Application to TB/HIV data
5.1 Introduction
In this chapter, after providing the details of a randomized placebo-controlled trial to
prevent TB in Ugandan adults infected with HIV, we will apply non-parametric methods,
the Cox PH model, Cox model with time-dependent variables, piecewise exponential model
and the AFT model to this dataset. We also give all the corresponding results and compare
the main methods: Cox model and AFT model.
Tuberculosis (TB) and acquired immunodeciency syndrome (AIDS) are two com-
pletely di¤erent diseases. TB is caused by the tubercle bacillus, Mycobacterium tubercu-
losis and spread through the air. TB attacks the lungs, but sometimes other parts of the
body too. AIDS is caused by human immunodeciency virus (HIV). HIV can be spread
by unprotected sexual relations, contaminated needles, breast milk, and transmission from
an infected mother to her baby at birth. HIV attacks the immune system. As the two
leading causes of infectious disease-associated mortality worldwide, TB and HIV diseases
have been bound together from the early years of the HIV/AIDS epidemic [19]. It has
been known that there is an interaction of TB and HIV infection. HIV infection is the
greatest known risk factor for progression of active TB disease [17] and reactivation of
latent TB infection [49], [44]. People infected with TB have only a 10% chance of ever
getting active TB in their lifetime. However, people infected with both HIV and TB have
a 50% chance of getting active TB in their lifetime [51]. HIV infection also increases TB
case fatality [1]. On the other hand, TB is a leading cause of morbidity and mortality in
population with high HIV prevalence. It has been shown that active TB promotes HIV
replication, increases virus load, and so accelerates HIV disease progression and mortality
[21], [54]. For these reasons, the prevention and treatment of TB in HIV infected people
is an important concern.
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Both the TB and HIV/AIDS global pandemics are staggering, particularly at the points
of HIV and TB coinfection [19]. The Joint United Nations Programme on HIV/AIDS
(UNAIDS) estimated that there were 33.2 million people living with HIV infection at the
end of 2007, increasing from 29 million in 2001, 2.5 million newly infected with HIV in 2007,
and 2.1 million deaths caused by HIV [29]. Sub-Saharan Africa remains the most seriously
a¤ected region by the AIDS pandemic, more than two-thirds of HIV-infected adults live
there and more than three fourth AIDS death in 2007 occurred there. With regard to TB,
the World Health Organization (WHO) estimated that there were 9.2 million new cases,
increasing from 9.1 million in 2005 and 1.7 millions deaths from TB worldwide in 2006, of
which around 0.7 millions (7.7%) cases and 0.2 millions deaths were HIV infected people
[61]. Twelve of 15 countries with the highest estimated TB incidence rates are in Africa,
which are partly explained by the relatively high rates of HIV coinfection [61].
The treatment of both TB and HIV infection have been enormously successful, but
there are still major diagnostic and therapeutic deciencies. After the introduction of
highly active antiretroviral therapy (HAART), the morbidity and mortality rates of HIV
infection are decreasing enormously in Europe and the USA [46]. However, HIV morbidity
and mortality rates are still increasing in some African and Asian countries, because of
the ine¤ective implementation of prevention and intervention policies [52]. The access to
antiretroviral drugs is limited in developing countries because of the high cost [30].
TB treatment comprises case treatment and preventive treatment. TB preventive ther-
apies has been recommended as a means of preventing TB in HIV-infected subjects [60]. It
aims to treat latent infection with Mycobacterium tuberculosis before active disease devel-
ops. Latent TB is diagnosed by a positive reaction to intradermal injection with puried
protein derivative (PPD, tuberculosis skin test). Because of the association of HIV with
TB, TB preventive therapy may be an important intervention to reduce the rising inci-
dence of TB and HIV in developing countries. Some studies [47], [56], [22], [58] have shown
that TB preventive therapy reduces the incidence of TB in HIV-infected adults. However,
few studies [41], [39] have assessed the e¤ect of TB preventive therapy on HIV progression
and mortality. No studies have shown a signicant e¤ect of TB preventive therapy on
mortality.
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5.2 Description of the dataset
5.2.1 Study population and objective
In March 1993 the Uganda-Case Western Reserve Research Collaboration began a ran-
domized, placebo-controlled clinical trial to assess the e¢ cacy of three regimens for the
preventions of TB in PPD-positive (at least 5 mm induration in PPD skin test) HIV-
infected Uganda adults. The three regimens were isoniazid for 6 months, isoniazid plus
rifampicin for 3 months, and isoniazid, rifampicin plus pyrazinamide for 3 months. In
October 1993 the study was expanded to include persons anergic (0 induration in reac-
tion to PPD and candida antigens) to both PPD and candida antigens based on studies
suggesting that there was an increased risk of tuberculosis in anergic HIV-infected adults
compared to PPD-positive groups [43], [50]. Between March 1993 and April 1995, 9095
subjects were screened and 2736 HIV-infected subjects were enrolled into the study. These
eligible subjects included 18-50 year old HIV infected males and non-pregnant females with
a positive PPD skin test or anergy, and a Karnofsky performance scale score greater than
50: Of the 6309 subjects screened but excluded for the study, 4306 subjects did not com-
plete the baseline evaluation and 2053 subjects were ineligible from the study for various
detailed in Figure 5.1. More detailed information regarding the study design, intervention,
measurement and the study proles has been published [58], [28].
PPD-positive subjects were randomly assigned to receive either placebo (250 mg of
ascorbic acid) daily for 6 months; isoniazid 300 mg daily for 6 months (6H); isoniazid 300 mg
and rifampicin 600 mg daily for 3 months (3HR); or isoniazid 300 mg, rifampicin 600 mg and
pyrazinamide 200 mg daily for 3 months (3HRZ). Anergic subjects were randomly assigned
to receive either placebo (250 mg of ascorbic acid), or isoniazid 300 mg daily for 6 months
(6H) by a separate but identical process. The study medications were dispensed monthly.
Subjects were followed monthly during study therapy and every 3 months thereafter. The
last date of follow-up was August 8, 1998.
In original studies [58], [28], the study objectives were to determine the e¢ cacy of the
three regimens of TB preventive therapy for TB in HIV-infected adults. In another study
[39], the e¤ect of the TB preventive therapy on HIV disease progression to AIDS and
survival was studied, and the signicant prognostic factors for HIV disease progression to
AIDS were identied. Only non-parametric method (K-M estimate and the log-rank test)
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and the Cox PH model were applied in this study. The association between the number
of initial HIV-related signs at baseline and the AIDS progression or mortality was shown
to be signicant [39]. Based on this result, we use a sub-dataset excluding subjects with
any baseline signs related to HIV. Of 2736 original subjects, 2158 participants have no
HIV-related signs and 491 participants have one and 81 participants have two HIV-related
signs. We only include 2158 subjects without any baseline signs or symptoms in current
analysis. Figure 5.1 gives the details of study prole in the current analysis. We apply
non-parametric methods, the Cox PH model, Cox model with time-dependent variables,
piecewise exponential model and the AFT model to this sub-dataset.
The objective of this study is to see the e¤ect of the TB preventive therapy on HIV
disease progression to AIDS and survival in HIV-infected adults without baseline HIV-
related signs. Using this analysis, we will compare the Cox models and the AFT models.
5.2.2 Study outcomes
In this analysis, the primary outcome is (a) HIV disease progression to AIDS, (b) death,
and (c) the combined event of AIDS progression and death. The outcome measures are
stratied by anergy status (PPD positive and anergic).
In our study, the criteria for AIDS progression are based mainly on the 1990 WHO
classication system for HIV/AIDS [59] and AIDS progression event is dened when a
patient develops any one major sign or three or more minor signs during follow up. Major
signs are dened as Karnofsky performance score less than or equal to 60, Kaposis sar-
coma, and esophageal candidiasis. The minor signs are dened as pruritic papules, oral
candidiasis, Varicella zoster virus, genital Herpes simplex, oral Herpes simplex, and TB.
This classication is obtained by a severity order of HIV-related signs based on CD4 lym-
phocyte counts. The classication is supported by the studies suggesting that HIV-infected
persons show many clinical signs as the disease progresses and there is a strong association
between HIV-related signs and CD4 lymphocyte counts [59], [42], [55].
The individual survival times for AIDS progression outcome are dened as the period
between enrollment in the study and the incidence date of the AIDS progression the last
clinic visit before the end of the study. The individual survival times for death outcome
are calculated from the start of the study to the date of death or to the date of the last
clinic visit before the end of study. The survival time for the combined event of AIDS
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Figure 5.1: Subjects enrolled in the study
progression and death are obtained from the enrollment in the study up to the date of
death or incidence date of the AIDS progression. Patients are censored at the last clinic
visit.
5.2.3 Description of variables
The variables and codes for this data are provided in the following table:
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Variables Description Codes/Values
AGE Age years
BCGscar BCGscar indicator 0 = no BCGscar, 1 = BCGscar
BMI Body mass index kg/m2
CREAT creatinine level mg/dl
EDUC Education length years
HCT Hematocrit level mg/dL
HGB Hemoglobin mg/dl
LYMPHABS Absolute lymphocytes counts cm 3
MARITAL Marital status 0 = never married, 1 = currently married,
2 = divorced/widowed.
PLT Platelet counts /L
Anergy Indicator of TB skin test induration 0 = (induration  5mm);
1 = (induration < 5mm):
SEX Sex 0 = female, 1 = male.
STUDYARM Six treatment arms 1 = Placebo, 2 = 6H, 3 = 3HR, 4 = 3HRZ,
5 = Anergic-Placebo, 6 = Anergic-6H.
SGOT Serum glutamic oxaloacetic transaminase U/L
WBC White blood cell cells/cm3
death censoring status 0 =censoring, 1 =death
survt survival time for AIDS progression year
5.3 Statistical analysis and results
5.3.1 Descriptive and non-parametric analysis
First, descriptive statistics are used to give us information about the distributions of the
variables. We get the baseline characteristics in 2158 participants using the descriptive
statistics (Table 5.1). Since there are 895 subjects missing for hematocrit level, we remove
this variable from the group of potential risk factors. We then get the cross-tabulations
for the remaining variables with six treatment arms respectively (Table 5.2). In both
the PPD-positive and anergy cohorts the treatment groups are approximately balanced
at baseline in terms of demographic factors and the laboratory test. Some continuous
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Characteristic n(%); mean(SD)
Male 680(32%)
Age 30(±6.5)
Marital status
Never married 260(12%)
Current married 943(44%)
Divorce/widow 949(44%)
BCG scar 1413(66%)
Anergic 503(23%)
Education 8 (±3.3)
Body Mass Index(kg/m2) 22.3(±3.6)
Hemoglobin(mg/dl) 12.7(±2.8)
Plalet count(/L) 259.7(±86.9)
Creatinine(mg/dl) 0.88(±0.22)
AST/SGOT(U/L) 26.4(±10.4)
Absolute lymphocyte count 2.27(±0.94)
white blood cell 5.6(±1.8)
Note: Anergic is an indicator of TB skin test induration less
than 5 mm.
Table 5.1: Baseline characteristics in 2158 participants
variables are grouped into categories according to clinical meaning. We categorize BMI
into three categories BMI  19, 19 < BMI  25, and BMI > 25. SGOT is categorized into
two categories SGOT  40 and SGOT > 40. When doing so, we use the established cut-
points that have clinical meaning and we also ensure that each group contains an adequate
number of individuals.
Survival time distributions for incident AIDS and death is estimated for each arm using
the K-M method (Section 2.1) and compared using the log-rank test (Section 2.2). The K-
M curves for each study arm provide a initial insight into the shape of the survival function
for each treatment arm. The log-rank test is used to compare survival time distributions
among treatment arms.
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PPD-positive Anergy
Characteristics
Placebo
(n=398)
6H
(n=421)
3HR
(n=453)
3HRZ
(n=382)
Placebo
(n=227)
6H
(n=277)
male,% 124(31%) 132(31%) 135(30%) 134(35%) 71(31%) 84(30%)
BCG scar, % 261(66%) 287(69%) 299(66%) 245(65%) 144(63%) 177(64%)
mean education,
years
7.9(±3.39) 8.1(±3.20) 7.9(±3.42) 7.8(±3.31) 8.2(±3.23) 7.9(±3.56)
mean age, years 30(±6.62) 30(±6.30) 30(±6.40) 29(±5.89) 30(±6.77) 29(±7.04)
Body mass index 23.0(±3.53) 22.9(±3.78) 23.3(±3.81) 22.8(±3.27) 22.3(±3.57) 22.0(±3.34)
Hemoglobin,
mg/dL
12.7(±1.9) 12.7(±1.94) 12.8(±1.89) 12.7(±1.96) 12.7(±1.82) 12.4(±1.91)
Platelet count, /L 262(±85.64) 257(±78.90) 263(±91.58) 261(±90.92) 259(±81.29) 255(±92.00)
Creatinine, mg/dL 0.89(±0.24) 0.89(±0.22) 0.88(±0.23) 0.89(±0.22) 0.83(±0.20) 0.84(±0.19)
AST/SGOT, U/L 26.6(±11.05) 26.8(±10.38) 25.4(±9.34) 25.9(±10.24) 27.1(±10.89) 27.2(±10.75)
Absolute
lymphocyte count
2.29(±0.85) 2.35(±0.78) 2.34(±0.82) 2.25(±0.70) 2.07± (0.86) 2.22(±1.59)
white blood cell 5.64(±1.81) 5.73(±1.70) 5.77(±1.95) 5.52(±1.60) 5.31(±1.57) 5.54(±1.73)
Note: PPD=purified protein derivative; 6H=isoniazid (INH) for 6 months; 3HR=INH plus rifampicin for 3 months;
3HRZ=INH plus rifampicin plus pyrazinamide for 3 months.
The body mass index was calculated as the weight in kilograms divided by the square of the height in meters.
Table 5.2: Baseline characteristics by anergic status in 2158 participants
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Figure 5.2: K-M curves for the time to AIDS progression among the TB preventive treat-
ment regimens
By the log-rank test, in the PPD-positive cohorts, there is no signicant di¤erence
in the cumulative incidence of AIDS progression among TB preventive treatment arms
(p = 0:2805). The same is in the anergic cohorts (p = 0:3922). The K-M curves also shows
the same result as the log-rank test (Figure 5.2). The K-M curves for time to death and
time to combined event of AIDS progression and death are presented (Figure 5.3 and 5.4).
The results of these three kinds of endpoints are very similar.
5.3.2 Cox PH model
We use univariate analysis to check all the risk factors before proceeding to more compli-
cated models. We use a univariate Cox proportional hazards regression for every potential
risk factor. The Wald test is considered in each univariate Cox PH model. Variables are
identied as signicant using a 0.1 signicance level in the univariate model. We then t the
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Figure 5.3: Time to death among the TB preventive treatment regimens
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Figure 5.4: Time to AIDS progression or death among the TB preventive treatment regi-
mens
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full multivariate Cox PH model including all the potential risk factors and treatment arms.
In univariate and the full multivariate proportional hazards models, age, hemoglobin, body
mass index, sex, SGOT, and absolute lymphocyte count show a statistically signicant as-
sociation with disease progression to AIDS. But other characteristics such as education,
marital status, creatinine level and platelet counts are not statistically signicant, suggest-
ing that these variable are not associated with the AIDS progression. So we will consider
the model which includes all the signicant predictors. The categorical predictor body
mass index has three levels and therefore we will include this predictor using two dummy
variables (BMIB2; BMIB3) with the group 19 < BMI  25 as the reference group. After
we built a multivariate model of main e¤ects, we then check all the interactions between
predictors. To consider the e¤ect of TB preventive therapy on AIDS progression, we in-
clude the study arms in the nal model. The treatment regimens (STUDYARM) have six
levels and therefore we will use ve dummy variables (STUDYARMA2i; STUDYARMA3i;
STUDYARMA4i STUDYARMA5i; STUDYARMA6i) with PPD positive-Placebo as the
reference group. The univariate and multivariate results of a PH model tted to this
dataset are obtained (Table 5.3). The nal multivariate Cox PH model is then given by
hi (t) = h0 (t) exp( 0:52LYMPHABS   0:25STUDY ARMA2i   0:15STUDY ARMA3i
  0:02STUDY ARMA4i + 0:26STUDY ARMA5i + 0:24STUDY ARMA6i + 0:02AGE
+ 0:68BMIB2   0:61BMIB3   0:32HGB   0:54SEX + 0:56SGOT ):
As expected from non-parametric test, TB preventive e¤ect is not statistically signif-
icant in PPD-positive cohort and anergic cohort even after adjusting age, hemoglobin,
body mass index, sex, SGOT and absolute lymphocyte count in a multivariate Cox PH
model. Among the PPD-positive patients, the hazard ratio for AIDS progression is 0.78
in 6H group, 0.86 in 3HR group and 0.98 in 3HRZ group compared with placebo group,
but they are not statistically signicant. Among the anergic group, the hazard ratio for
AIDS progression is exp (0:24  0:26) = 0:98 in 6H group relative to placebo group but not
statistically signicant. So there is no evidence that the TB preventive therapies have the
di¤erent e¤ect on AIDS progression through time. We can observe the similar result for
event of death and the combined event of AIDS progression or death after controlling age,
hemoglobin, body mass index, sex, SGOT and absolute lymphocyte count(Table 5.4).
After a Cox PH model is tted, the adequacy of this model, including the PH assump-
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Univarate analysis Mutivariate analysis
Covariates
β
HR 95%CI P-value
β
HR 95%CI P-value
PPD-positive
  Placebo 1 1
  6H -0.23 0.80 (0.56,1.14) 0.21 -0.25 0.78 (0.55,1.12) 0.18
  3HR -0.17 0.84 (0.60,1.19) 0.34 -0.15 0.86 (0.61,1.22) 0.40
  3HRZ 0.14 1.15 (0.81,1.63) 0.44 -0.02 0.98 (0.68,1.41) 0.92
Anergic
  placebo 0.52 1.68 (1.17,2.4) 0.005 0.26 1.30 (0.90,1.87) 0.16
  6H 0.69 2 (1.43,2.79) <.0001 0.24 1.28 (0.90,1.80) 0.17
AGE 0.02 1.02 (1.01,1.04) 0.01 0.02 1.02 (1.00,1.03) 0.02
BMI
19<BMI<=25 1 1
BMI<=19 1.05 2.87 (2.26,3.65) <.0001 0.68 1.98 (1.54-2.56) <.0001
BMI>25 -0.82 0.44 (0.31,0.62) <.0001 -0.61 0.54 (0.38-0.77) 0.0006
HGB -0.26 0.77 (0.73,0.81) <.0001 -0.32 0.72 (0.68-0.77) <.0001
Absolute
lymphocyte
count
-0.79 0.46 (0.39-0.54) <.0001 -0.52 0.60 (0.51-0.70) <.0001
SEX -0.23 0.80 (0.64-0.99) 0.037 -0.54 0.58 (0.46-0.74)
<.0001
SGOT 0.84 2.31 (1.74-3.08) <.0001 0.56 1.76 (1.30-2.38) <.0001
Table 5.3: Univariate and multivariate Cox PH model for the relative hazard of AIDS
progression
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AIDS progression Death AIDS progression or death
HR 95%CI P-value HR 95%CI P-value HR 95%CI P-value
PPD-positive
  Placebo 1 1 1
  6H 0.78 (0.55,1.12) 0.18 0.8 (0.56,1.14) 0.21 0.77 (0.54,1.08) 0.13
  3HR 0.86 (0.61,1.22) 0.40 0.88 (0.63,1.25) 0.48 0.83 (0.60,1.16) 0.27
  3HRZ 0.98 (0.68,1.41) 0.92 0.99 (0.70,1.41) 0.95 0.97 (0.69,1.36) 0.84
Anergic
  Placebo 1 1 1
  6H 0.98 (0.71,1.47) 0.92 0.97 (0.67,1.39) 0.86 0.96 (0.68,1.37) 0.84
Note: The hazard ratio is adjusted for age, body mass index, hemoglobin, absolute lymphocyte count,
sex, and SGOT in a Cox PH model.
Placebo is the reference group.
Table 5.4: Multivariate Cox PH model for the relative hazard of AIDS progression, death,
and combination of AIDS progression or death
tion and the goodness of t, needs to be assessed. The PH assumption checking with
graphical method and two statistical test methods (adding time-dependent covariates in
the Cox model and tests based on the Schoenfeld residuals have been described in Section
3.3. We use log(  log(survival)) plot (Section 3.3.1) to check the PH assumption for all
the categorical variables. There is no evidence that the PH assumption is violated for any
categorical variables. We also create the time-dependent covariate by creating interactions
of the predictors and survival time and include them in the model (Section 3.3.2). The
result indicates that the PH assumption for LYMPHABS is violated (p-value for LYM-
PHABS  t is less than .0001). The Schoenfeld residuals are also used to check the PH
assumption (Section 3.3.3). We check the p-value for testing whether the correlation be-
tween Schoenfeld residual for this covariate and ranked survival time is zero. The p-values
for LYMPHABS is less than .0001 and greater than 0.05 for all the other covariates, which
suggesting that the PH assumption is violated for LYMPHABS, but reasonable for all the
other covariates.
We assess goodness of t by residual plots (Section 3.4). A plot of the Cox-Snell
residuals against the cumulative hazard of Cox-Snell residuals is presented (Figure 5.5).
There is some evidence of a systematic deviation from the straight line, which gives us some
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Figure 5.5: Cumulative hazard plot of the Cox-Snell residual for Cox PH model
concern about the adequacy of the tted model. The plot of deviance residual against the
risk score shows that the deviance residuals seem not to be symmetrically distributed
about zero. There are very high or very low deviance residuals which suggest that these
observations may be outliers. (Figure 5.6). Therefore, we have some concern about the
adequacy of the tted Cox PH model. We also use delta-beta statistic to measure the
inuential observations on the model as a whole. It shows that the coe¢ cient does not
change too much when the observations corresponding to the largest delta-beta statistics
are removed. Therefore, we do not remove them from the dataset and conclude that there
are no inuential observations.
5.3.3 Cox model with time-dependent variables
We have shown that the Cox model displayed nonproportionality for variable LYMPHABS.
We believe that there is an interaction between LYMPHABS and time. It is not appro-
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Figure 5.6: Deviance residuals plotted against the risk score for Cox PH model
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Year
variable 0-0.5 0.5-1year 1-2 years 2-3 years >3 years
g1(t) 0 1 0 0 0
g2(t) 0 0 1 0 0
g3(t) 0 0 0 1 0
g4(t) 0 0 0 0 1
Table 5.5: Time-dependent covariates represent di¤erent time periods
priate to use stratied Cox model because LYMPHABS is a continuous variable. We then
incorporate time-dependent covariate into the model (Section 3.5.2).
We may dene X(t) =LYMPHABSt and formulate a model (model A):
h(t;x(t)) = h0 (t) fexp(LLYMPHABS + 1(LYMPHABS  t) + 0x)g;
where x is the vector of all the xed covariates (age, study arms, hemoglobin, body mass
index, sex and SGOT) and  is the corresponding vector of the regression coe¢ cient for
the xed covariates. The e¤ect of LYMPHABS is exp(L + 1t). L can be interpreted
as the e¤ect of LYMPHABS at study enrollment. This model states that the e¤ect of
LYMPHABS is assumed to increase or decrease linearly in relation to time.
Alternatively, the proportional hazards assumption may hold at least approximately
over short time periods instead of the entire time period. In this situation, hazard ratio
of LYMPHABS may change at discrete intervals. We partitioned the time period into 5
sub-periods and created ve binary, time-dependent covariates to represent them (Table
5.5). The rst interval goes from 0 to half of a year; the second time interval goes from
half to one year; the third time interval goes from 1 year to 2 years; the fourth interval
goes from 2 to 3 years; and the last interval goes from 3 years onward. This model assumes
that there are ve di¤erent hazard ratios estimates in ve intervals.
The Cox non-PH model is tted as follows:
h(t;x(t)) = h0 (t) expfLLYMPHABS + 1(LYMPHABS  g1 (t)) + 2(LYMPHABS  g2 (t))
+ 3(LYMPHABS  g3 (t)) + 4(LYMPHABS  g4 (t)) + 0xg:
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Period δ HR P-value 95%CI
0-6 months -1.09 0.34 <.0001 (0.23-0.49)
6-12 months 0.26 0.44 <.0001 (0.31-0.61)
1-2 years 0.53 0.57 <.0001 (0.43-0.76)
2-3 years 1.10 1.02 0.92 (0.76-1.36)
>3 years 1.16 1.07 0.83 (0.55-2.08)
HR= hazard ratio CI= confidence interval
Table 5.6: Time-dependent e¤ect of absolute lymphocyte count (LYMPHABS) in ve time
intervals
where x is the vector of all the xed covariates (age, study arms, hemoglobin, body mass
index, sex and SGOT) and  is the corresponding vector of the regression coe¢ cient for
the xed covariates. The non-PH model allows the e¤ect of LYMPHABS varies with time
periods. The coe¢ cients 1 to 4 denote the interaction e¤ect between LYMPHABS and
time. The e¤ect of LYMPHABS in the rst half year is given by exp(L). The e¤ect of
LYMPHABS in the subsequent period are estimated by exp(1 + i); i = 1; 2; 3; 4. The
results are presented in Table 5.6.
The result shows a signicant e¤ect of LYMPHABS below 2 years and a nonsignicant
e¤ect of LYMPHABS after 2 years. Hazard ratios in the rst three time intervals are
similar and hazard ratios for the last two time intervals are similar, we therefore separate
the data into two time intervals. We use one Heaviside function g (t), where
g (t) :=
8<: 0 if t  21 if t > 2 :
The tted model (model B) with time-dependent variables are
h(t;x(t)) = expf 0:73LYMPHABS + 0:77(LYMPHABS  g (t)) +0xg:
Tables 5.7 gives the results of model A: the Cox non-PH model with smooth time-
dependent hazard ratio and model B: the Cox non-PH model with discrete time interval.
In model A, the hazard ratios for the e¤ect of LYMPHABS in each time interval,
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Smooth Cox non-PH model Piecewise Cox non-PH model
Variables β HR 95%CI P-value β HR 95%CI P-value
PPD-positive
  Placebo 1 1
  6H -0.25 0.78 (0.55,1.12) 0.18 -0.24 0.78 (0.55,1.12) 0.17
  3HR -0.13 0.88 (0.62,1.24) 0.47 -0.13 0.87 (0.62,1.24) 0.45
  3HRZ 0.01 0.95 (0.72,1.49) 0.95 0.003 1.03 (0.71,1.43) 0.98
Anergic
  Placebo 0.26 1.29 (0.90,1.86) 0.17 0.26 1.29 (0.90,1.86) 0.17
  6H 0.27 1.31 (0.93,1.86) 0.12 0.26 1.30 (0.92,1.94) 0.13
AGE 0.02 1.02 (0.93,1.86) 0.03 0.02 1.02 (1.00,1.03) 0.03
BMI
19<BMI<=25 1 1
  BMI<=19 0.65 1.92 (1.48,2.48) <.0001 0.67 1.95 (1.51,2.51) <.0001
  BMI>25 -0.62 0.54 (0.38,0.76) 0.0005 -0.62 0.54 (0.38,0.77) 0.0006
HGB -0.32 0.73 (0.69,0.77) <.0001 -0.32 0.73 (0.69,0.77) <.0001
SEX -0.54 0.58 (0.46,0.74) <.0001 -0.54 0.58 (0.46,0.74) 0.0004
SGOTX 0.57 1.77 (1.31,2.39) 0.0002 0.58 1.78 (1.32,2.40) 0.0002
LYMPHABS -1.08 0.34 (0.25,0.47) <.0001 -0.73 0.48 (0.40,0.58) <.0001
LYMPHABS*t 0.40 1.50 (1.27,1.76) <.0001
LYMPHABS*g(t) 0.77 2.23 (1.57,2.97) <.0001
-2loglikelihood 4878.172 4879.781
Note: LYMPHABS= Absolute lymphocyte count.
g(t) is the heaviside function, which is zero when time is less than or equal to 2 years and 1 when time is greater
than 2 years.
Table 5.7: Cox models with time-dependent covariates
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Period β HR P-value 95%CI
0-2 years -0.73 0.48 <.0001 (0.40-0.58)
>2 years 0.04 1.04 0.75 (0.80-1.35)
Table 5.8: Time-dependent e¤ect of LYMPHABS in two time intervals
controlling all the other covariates is given as follows:
HR = exp(L + 1t) = exp ( 1:08 + 0:4t) :
1 = 0:4 is positive, which indicates that the e¤ect of LYMPHABS increases linearly
with time. When time = 1; HR = exp( 1:08 + 0:4  1) = 0:51; when time = 2; HR =
exp( 1:08 + 0:4  2) = 0:76; when time = 3; HR = exp( 1:08 + 0:4  3) = 1:13: In the
rst two years, HR less than one indicates that the AIDS progression hazard decreases as
the value of the LYMPHABS increases. After two years, HR greater than 1 indicates the
LYMPHABS is positively associated with the AIDS progression probability.
In model B, we dene one cut point (2 years) on the time axis. The two hazard
ratios are given by separately exponentiating each of the two estimated coe¢ cients. When
time is less than 2 years, dHR = exp( 0:73) = 0:48. When time is greater than 2 years,dHR = exp( 0:73 + 0:77) = exp(0:04) = 1:04. We can obtain that the 95% condence
interval for the two hazard ratios are (0.40-0.58) and (0.80-1.35) manually based on the
tted model B. The 95% condence interval in the rst two years does not include one,
which means the e¤ect of LYMPHABS is statistically signicant. The 95% condence
interval includes one after two years, which means that the e¤ect of LYMPHABS is not
statistically signicant any more after two years. The estimated LYMPHABS e¤ects are
presented in Table 5.8. Therefore, the hazard ratio decreases by 1/2 when LYMPHABS
increases by one unit in the rst two years. After two years, there is no evidence that
LYMPHABS has an e¤ect on AIDS progression. The estimated treatment e¤ects are
similar in two models. The results are also very similar to the Cox PH model except for
the e¤ect of LYMPHABS.
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Figure 5.7: Q-Q plot for time to AIDS progression
5.3.4 AFT model
The accelerated failure time (AFT) model is another alternative of the Cox PH model when
the PH assumption is violated. The AFT model can be used to express the magnitude
of e¤ect in a more accessible way in terms of di¤erence between treatment in survival
time. We t the dataset using exponential, Weibull, log-logistic, log-normal and gamma
AFT model. For each kind of model, we t both the univariate and multivariate AFT
model. In both univariate and multivariate AFT models, age, hemoglobin, body mass
index, sex, SGOT, and absolute lymphocyte count are statistically signicantly associated
with disease progression to AIDS. No interactions are statistically signicant in multivariate
AFT models. The results from the di¤erent AFT models applied to the time to AIDS
progression are presented in Table 5.9. There is no big di¤erence for the estimations in
di¤erent models.
The Q-Q plot (Section 4.2.7) is used to check the AFT assumption. The Q-Q plot in
Figure 5.7 approximates well to a straight line from the origin indicating that the AFT
model may provide an appropriate model.
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Table 5.9: Results from AFT models for time to AIDS progression
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No of parameters Log-likelihood Testing against the Gamma distribution
Distribution m L LR df
Exponential 1 -1103.797 47.902 2
Weibull 2 -1095.900 32.108 1
Log-Normal 2 -1081.191 2.690 1
Gamma 3 -1079.846
Log-logistic 2 -1079.740 Not nested
Table 5.10: The log-likelihoods and likelihood ratio (LR) tests, for comparing alternative
AFT models
Distribution Log-likelihood k c AIC
Exponential -1103.797 12 1 2233.594
Weibull -1095.900 12 2 2219.800
Log-Normal -1081.191 12 2 2190.382
Gamma -1079.846 12 3 2189.692
Log-Logistic -1079.740 12 2 2187.480
Table 5.11: Akaike Information Criterion (AIC) in the AFT models
We compared all these AFT models using statistical criteria (likelihood ratio test and
AIC). The nested AFT models can be compared using the likelihood ratio (LR) test. The
exponential model, the Weibull model and the log-normal model are nested within the
gamma model (Table 5.10).
According to the LR test, the log-normal model ts better. However, the LR test is not
valid for comparing models that are not nested. In this case, we use AIC to compare the
models (Table 5.11) (The smaller AIC is the better). The log-logistic AFT model appears
to be an appropriate AFT model according to AIC compared with other AFT models,
although it is only slightly better than log-normal or Gamma model. We also note that
the Weibull and exponential model are poorer ts according to LR test and AIC. This
provides more evidence that the PH assumption for this data is not appropriate.
Furthermore, we check the goodness of t of the model using residual plots. The
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Figure 5.8: Cumulative hazard plot of the Cox-Snell residual for log-logistic AFT model
cumulative hazard plot of the Cox-Snell residuals in log-logistic model is presented in
Figure 5.8. The plotted points lie on a line that has a unit slope and zero intercept.
So there is no reason to doubt the suitability of this tted log-logistic model. At last,
we conclude that the log-logistic model is the best tting the AFT model based on AIC
criteria and residuals plot.
Under the log-logistic AFT model, in PPD-positive cohort, the estimated acceleration
factor for an individual in 6H group, 3H group and 3HRZ group relative to an individual
in placebo group is 1.23, 1.15, 0.99 respectively. This indicates that the e¤ect of 6H, 3HR
prolongs the time to AIDS progression, but the e¤ect of 3HRZ speeds up the time to AIDS
progression. However, they are not statistically signicant. In the anergic cohort, the e¤ect
of placebo appears to slow down the time to AIDS progression but it is nonsignicant. We
can calculate the acceleration factors and the corresponding condence interval for every
pair of groups manually. We can also obtain these by retting the model in which di¤erent
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dummy variables for treatment regimens are created.
The acceleration factor for age is 0.99, which indicates that the earlier AIDS progression
and shorter survival time are more likely for the older persons. The time ratio for HGB and
LYMPHABS above 1 implies that these variables prolong the time to AIDS progression as
they increase. Men have longer survival time and AIDS progression time than women. The
SGOT higher than 40 U/L in a HIV-infected patient speeds up AIDS disease progression
and mortality than that less than 40 U/L. The patient with BMI less than 19 has shorter
AIDS progression than patients with normal BMI, but the patients with BMI above 25
has longer AIDS progression than patients with BMI with normal BMI.
We now derive model-based predictions. From equation (4.13), the median survival time
for the ith individual under the log-logistic model is given by t (50) = exp( + xi): For
the individual (STUDYARMAi = 0; i = 2; :::; 6; mean age = 30, BMIB2 = 0; BMIB3 = 0;
mean HGB = 12:7, mean LYMPHABS = 2:27, sex = 0, SGOT = 0), the estimated median
survival time for this individual in placebo group in PPD positive cohort is
exp( 2:97  0:01 30 + 0:32 12:7 + 0:44 2:27) = 6:01:
The estimated median survival time for a individual (STUDYARMA2 = 1; STUDYARMAi =
0; i = 3; :::; 6; mean age = 30, BMIB2 = 0; BMIB3 = 0; mean HGB = 12:7, mean LYM-
PHABS = 2:27, sex = 0, SGOT = 0) in 6H group in PPD positive cohort is
exp( 2:97 + 0:21 1  0:01 30 + 0:32 12:7 + 0:44 2:27) = 7:41:
Note that the ratio of the two median time is the acceleration factor for 6H group
compared with placebo group, which is 1.23.
Instead of predicting survival time, we often want to predict the probability of surviving
to some specied time. For example, the ve year survival probabilities for every individual
in this data can be obtained. Table 5.12 shows the rst 10 cases of this dataset. The last
column (PROB) contains the ve year survival probabilities based on the tted log-logistic
model.
Using equation (4.11), the tted survival function for the ith individual is
bSi (t) = n1 + t 1b exp(bi)o 1 = n1 + t 10:71 exp(bi)o 1 ;
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where
bi =    bxib
=
1
0:71
2:97  0:21STUDY ARMA2   0:14STUDY ARMA3 + 0:01STUDY ARMA4
+ 0:29STUDY ARMA5 + 0:33STUDY ARMA6 + 0:01AGE + 0:54BMIB2
  0:44BMIB3   0:32HGB   0:44LYMPHABS   0:65SEX + 0:58SGOTg:
Using equation (4.12), the corresponding estimated hazard function for the ith indi-
vidual is
bhi (t) = 1btf1 + t  1b exp( bi)g 1
=
1
0:71t
f1 + t  10:71 exp ( bi)g:
Note that the exponential and Weibull AFT models are also PH models. The signs of
the coe¢ cients in the AFT model are opposite to the signs for the PH model. The estimate
of shape parameter in Weibull model is 1.2 which is greater than 1, and the 95% CI is
(1.10,1.31) which does not cover the null value of 1. This suggests that the Weibull model
may be better than the exponential model. Therefore we only compare Weibull AFT model
and PH model here. Using equation (4.6), we can calculate the regression coe¢ cients in
Weibull PH model. The correspondence between the parameters of the Weibull PH and
AFT models are presented in Table 5.13.
The estimated median survival time of the particular individual under the Weibull AFT
model, from equation (4.8), is
t (50) = exp f log (log 2) + + xig :
The estimated median survival time for an individual in placebo group in PPD positive
cohort after adjusting all the other covariates(STUDYARMAi = 0; i = 2; :::; 6; mean age
= 30, BMIB2 = 0; BMIB3 = 0; mean HGB = 12:7, mean LYMPHABS = 2:27, sex = 0,
SGOT = 0) is given by
expf0:83 log (log 2)  1:85  0:01 30 + 0:27 12:7 + 0:42 2:27g = 6:05:
The estimated median survival time for a individual in 6H group in PPD positive cohort
is
expf0:83 log (log 2)  1:85 + 0:18 1  0:01 30 + 0:27 12:7 + 0:42 2:27g = 7:24:
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The ratio of the two medians is 1.20.
From equation (4.4), the estimated survival function for the ith individual is given by
bSi (t) = expn t 1b b&io ;
where
b&i =    bxib
=
1
0:83
(1:85  0:18STUDY ARMA2   0:12STUDY ARMA3 + 0:01STUDY ARMA4
+ 0:24STUDY ARMA5 + 0:22STUDY ARMA6 + 0:01AGE + 0:57BMIB2
  0:50BMIB3   0:27HGB   0:42LYMPHABS   0:45SEX + 0:50SGOT ):
From equation (4.7), the estimated hazard function for the ith individual is by
bhi (t) = bhi (t) = b 1tb 1 1 exp(b&i)
=
1
0:83
t
1
0:83
 1 exp(b&i): (5.1)
We can also obtain this by the PH representation of the Weibull model. The estimated
hazard function for the ith individual is
bhi (t) = t 1 exp(0xi)
=  2:23 1
0:83
t
1
0:83
 1 exp(0:22STUDY ARMA2   0:14STUDY ARMA3   0:01STUDY ARMA4
  0:29STUDY ARMA5   0:26STUDY ARMA6   0:02AGE   0:69BMIB2 + 0:60BMIB3
+ 0:33HGB + 0:51LYMPHABS + 0:54SEX   0:60SGOT ):
This turns out to be the same as equation (5.1).
We also t the log-logistic AFT model for time to death and time to combination of
AIDS and death. The results (see Table 5.14) for three kinds of events are very similar.
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Obs A2 A3 A4 A5 A6 AGE B2 B3 HGB LYMPHABS SEX SGOTX death t prob
1 0 0 1 0 0 34 0 1 13.5 3.9 1 0 1 5 0.952
2 0 0 0 0 0 26 0 0 10.3 2 1 0 1 5 0.470
3 1 0 0 0 0 20 1 0 12.3 2.2 1 0 0 5 0.632
4 0 1 0 0 0 33 0 0 11.2 1.3 1 0 0 5 0.483
5 0 0 0 0 0 28 0 1 14.4 2.1 1 0 0 5 0.916
6 0 1 0 0 0 32 0 0 13.1 2.8 1 0 1 5 0.851
7 1 0 0 0 0 24 0 0 11 2.4 1 0 0 5 0.685
8 0 0 0 0 0 24 0 0 13.9 1.6 1 0 0 5 0.784
9 0 0 1 0 0 31 0 0 12.1 1.8 1 0 0 5 0.615
10 1 0 0 0 0 27 0 0 10.6 3.8 1 0 0 5 0.805
Table 5.12: Predicted 5 year survival probabilities for the rst ten individuals based on
log-logistic AFT model
5.3.5 Piecewise exponential model
All the AFT models we have considered assume that the hazard is a smooth function
of time. The Cox model lacks the capability to test the shape of the hazard function.
Alternatively, the underlying hazard function may be approximated by a step function.
The piecewise exponential model (Section 4.1.2) can be used to describe both the e¤ect of
covariates and underlying hazard rate.
We rst break up the whole follow-up period into ve intervals of 1 year each and
assume that the hazard is constant within each interval. We then create a new dataset
with possibly multiple records for each person. And the time variable is coded as the
length of time from the start of the interval until death. There is a certain arbitrariness
that arises from the division of the observation period into intervals. To increase reliability
in the result, we try other divisions and see if the results are stable. We reestimate the
model with the division into 3 intervals of 2 years each. The likelihood ratio test is used
to test the signicant e¤ect of interval by rerunning the model without variable intervals.
The results of the piecewise exponential model is in Table 5.15. For the ve interval
piecewise exponential model, the likelihood ratio test shows a signicant e¤ect of interval
implying that the hazard is not constant over time. The coe¢ cients for the four indicator
variables are all compared with the rst interval. The pattern of the coe¢ cient estimates
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PH AFT
Variable β se HR 95%CI α se TR 95%CI
Intercept -1.85 0.41 (-2.66,-1.05)
PPD-positive
  Placebo 1 1
  6H -0.22 0.18 0.80 (-0.57,0.13) 0.18 0.15 1.20 (0.89,1.62)
  3HR -0.14 0.18 0.87 (-0.49,0.21) 0.12 0.15 1.13 (0.84,1.50)
  3HRZ 0.01 0.18 1.01 (-0.34,0.36) -0.01 0.15 0.99 (0.74,1.33)
Anergic 0.00
  Placebo 0.29 0.19 1.33 (-0.08,0.65) -0.24 0.79 (0.58,1.06)
  6H 0.26 0.18 1.30 (-0.08,0.61) -0.22 0.16 0.80 (0.60,1.07)
AGE 0.02 0.01 1.02 (-0.04,0.005) -0.01 0.01 0.99 (0.97,0.99)
BMI
19<BMI<=25 1 1
BMI<=19 0.69 0.14 1.99 (-0.96,0.42) -0.57 0.11 0.57 (0.45,0.70)
BMI>25 -0.60 0.18 0.55 (0.24,0.97) 0.50 0.15 1.65 (1.24,2.21)
HGB -0.33 0.02 0.72 (0.28,0.38) 0.27 0.03 1.31 (1.25,1.38)
LYMPHABS -0.51 0.08 0.60 (0.35,0.67) 0.42 0.07 1.53 (1.33,1.74)
SEX -0.54 0.12 0.58 (0.30,0.78) 0.45 0.10 1.56 (1.28,1.91)
SGOTX 0.60 0.16 1.82 (-0.91,-0.28) -0.50 0.13 0.61 (0.47,0.78)
Scale 9.28 22.13 (-34.1,52.6) 0.83 0.04 (0.76,0.91)
Shape 1.20 0.05 (1.10,1.31) 1.20 0.05 (1.10,1.31)
Table 5.13: Comparison of Weibull PH and AFT model
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AIDS progression Death AIDS progression or death
β 95%CI TR β 95%CI TR β 95%CI TR
PPD-positive
  Placebo 1 1 1
  6H 0.21 (0.89,1.62) 1.23 0.19 (0.91-1.6) 1.21 0.23 (0.95,1.65) 1.26
 3HR 0.14 (0.84,1.50) 1.15 0.12 (0.85,1.49) 1.13 0.18 (0.91,1.57) 1.20
  3HRZ -0.01 (0.74,1.33) 0.99 -0.02 (0.73,1.30) 0.98 0.02 (0.77,1.34) 1.02
Anergic
  Placebo 1 1 1
  6H -0.03 (0.71,1.32) 0.97 -0.02 (0.72,1.34) 0.98 0.0002 (0.74,1.35) 1.0002
Note: The time ratio (LR) is adjusted for age, body mass index, hemoglobin, absolute lymphocyte count, sex,
and SGOT in the log-logistic AFT model.
Placebo is the reference group.
Table 5.14: The log-logistic AFT models for time to AIDS progression, death, and the
combination of AIDS progression and death
is not monotonic. The estimated hazard increases from the rst year to the second year,
then decreases after two years. The Wald tests for the individual indicator variables show
that the hazard of death in the fourth year is signicantly lower than the rst year. For the
three interval piecewise exponential model, the likelihood ratio test shows a nonsignicant
e¤ect of interval. The pattern of the coe¢ cients is not monotonic either. The estimated
hazard increases from the rst interval to the second interval, then decreases.
The estimates for other xed covariates in two piecewise exponential models are virtu-
ally identical. But the likelihood ratio tests for the overall e¤ect of interval are di¤erent.
We have no condence to support one piecewise exponential model, but they can give us
some clue about the shape of the hazard function of survival time.
5.3.6 Conclusion
This study is based on a large number of participants from Uganda, where the prevalence of
HIV infection and TB are very high. This study shows that the benet of the TB preventive
therapies to delay HIV disease progression to AIDS and death for HIV-infected adults is
not conrmed, although they are e¤ective in reducing the incidence of TB. Association of
the TB preventive therapies with the AIDS progression is examined through the linkage
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Piecewise exponential model
Six intervals Three intervals
Variables estimate 95%CI P-value estimate 95%CI P-value
Intercept -2.01 (-2.95,-1.06) <.0001 -0.96 (-1.93,0.009) 0.05
PPD-positive
  Placebo
  6H 0.27 (-0.09,0.62) 0.14 0.26 (-0.10,0.61) 0.16
  3HR 0.18 (-0.17,0.52) 0.32 0.17 (-0.18,0.51) 0.34
  3HRZ 0.09 (-0.26,0.44) 0.61 0.04 (-0.31,0.39) 0.82
Anergic
  Placebo -0.23 (-0.59,0.14) 0.22 -0.25 (-0.61,0.11) 0.18
  6H -0.19 (-0.54,0.15) 0.27 -0.20 (-0.55,0.14) 0.25
AGE -0.02 (-0.03,-0.004) 0.01 -0.02 (-0.04,-0.005) 0.01
BMI
19<BMI<=25
BMI<=19 -0.64 (-0.89,-0.38) <.0001 -0.71 (-0.97,-0.46) <.0001
BMI>25 0.57 (0.23,0.92) 0.0012 0.62 (0.27,0.97) 0.0005
HGB 0.31 (0.26,0.37) <.0001 0.24 (0.18,0.29) <.0001
LYMPHABS 0.48 (0.32,0.63) <.0001 0.53 (0.37,0.69) <.0001
SEX 0.51 (0.28,0.75) <.0001 0.40 (0.16,0.64) 0.001
SGOTX -0.50 (-0.80,-0.20) 0.0011 -0.56 (-0.86,-0.26) 0.0002
j2 -0.12 (-0.36,0.12) 0.32 -0.21 (-0.44,0.02) 0.09
j3 -0.05 (-0.33,0.23) 0.73 -0.13 (-0.40,0.15) 0.36
j4 0.69 (0.16,1.23) 0.01
j5 1.22 (-0.75,3.19) 0.23
Table 5.15: Summary of the piecewise exponential models
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of the signs and symptoms to replication of HIV virus.
A nding of the present study is the absence of protection of TB preventive therapies
on AIDS progression, death and combined event of AIDS progression and death. This
study presents similar estimates of risk for the covariates with the previous study with the
baseline signs/ symptoms variables in the Cox PH model [39]. But the PH assumption does
not hold for LYMPHABS in this analysis. To overcome this, time-dependent covariates
are incorporated into the Cox model. We also use ve di¤erent AFT models to t the
data. We nd that the log-logistic AFT model t better for this dataset. We provide the
predicted hazard functions, predicted survival functions, median survival times and time
ratios under the log-logistic AFT model.
In our study, age, anergic status, hemoglobin, body mass index, sex, SGOT and ab-
solute lymphocytes count are signicantly associated with the AIDS progression. The older
person is prone to have shorter survival time and AIDS progression time. Men have longer
survival time and AIDS progression time than women. The risks of AIDS progression,
death and the combined event of AIDS progression and death are higher among anergic
participants than among PPD-positive participants. HIV-infected participants with SGOT
higher than 40 U/L have more rapid AIDS disease progression and mortality than those
less than 40 U/L. The AIDS progression prolongs as hemoglobin increases. According to
the Cox model with time-dependent variables, the predictive e¤ect of absolute lympho-
cytes count clearly changes at about 2 years. Before 2 years, the hazard is less than one,
which indicates that the risk of AIDS progression decreases as absolute lymphocyte count
increases. After 2 years, the hazard is greater than one, which indicates that the risk
of AIDS progression increases as absolute lymphocyte count increases. According to the
log-logistic AFT model, LYMPHABS prolongs the time to AIDS progression as it increases.
The PH model is routinely applied to the analysis of survival data. The study consid-
ered here provides an example of a situation where PH model is inappropriate and where
the AFT model provides a better description of the data. We have seen that the AFT
model is a more valuable and realistic alternative to the PH model in some situations.
Furthermore, the AFT model makes it possible for clinicians to interpret the treatment
benet in terms of an e¤ect on expected duration of illness. To this content the AFT model
may have explanatory advantage in that covariates have a direct e¤ect on survival times
rather on hazard functions as in the PH model.
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Chapter 6
Discussion
The Cox PH model is the most widely used way of analyzing survival data in clinical
research. In a review paper of survival analysis published in cancer journals [4], it was
found that only ve percent of all studies using the Cox PH models check PH assumption.
However PH assumption is not always satised in the data. If this assumption does not
hold there are various solutions to consider. One solution is to include the time-dependent
variable for the predictors with non-proportional hazards. When this approach is used
to account for a variable with non-proportionality, di¤erent results may be obtained from
di¤erent choices of time-dependent variables. It is hard to choose between models. Alter-
natively we can use a model where we stratify on the non-proportional predictors. The
stratied Cox model is not appropriate when the covariate with non-proportionality is con-
tinuous or of direct interests. And both ways are still based on comparison of hazards. The
AFT model is an alternative method for the analysis of survival data even when hazards
are not proportional. Based on asymptotic results, the AFT models should lead to more
e¢ cient parameter estimates than Cox model under certain circumferences [14], [45].
The Cox model expresses the multiplicative e¤ect of covariates on the hazard. The AFT
model provides an estimate of the median survival time ratios. The results from an AFT
model are easier to interpret, more relevant to clinicians and provide a more appropriate
description of survival data in many situations. The comparison of the Cox PH model and
the AFT models are presented in Table 6.1.
In this thesis, we have analyzed the TB/HIV dataset using these alternative methods.
This study provides an example of a situation where the PH model is inappropriate and
where the AFT model provides a better description of the data. The PH assumption does
not hold in this dataset. After tting the Cox PH model, the goodness of t of the model is
assessed through residual plots. The PH model seems to display lack of t in this example.
In contrast, the AFT model provides an adequate description of the data. The family of
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Cox PH model AFT model
Advantage
1) Widely used.
2) No assumption about the
distribution for the survival
time.
3) Survival curves can be
estimated after adjusting for
the explanatory variables.
4) Incorporation of
time-dependent covariate is
convenient using SAS
software.
1) More informative. predicted hazard
functions, predicted survival functions,
median survival times and time ratios
can be obtained.
2) The effect of covariate is to accelerate
or delay the duration of illness by a
constant  amount (acceleration factor
or time ratio).
3) The effect size is time ratio which is
easier to interpret and more relevant
to clinician.
Disadvantage
1) PH assumption must hold.
2) Effect size is hazard ratio
which is less relevant to
clinician.
1) Relatively unfamilar and rarely used.
2) AFT assumption must hold .
3) Need to specify the distribution of
survival time, but an appropriate
distribution may be difficult to
indentify.
4) Incoporation of time-dependent
covariate is not allowed using SAS
software.
Table 6.1: Comparison of Cox PH model and AFT model
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the AFT models containing the exponential AFT model, Weibull AFT model, log-logistic
AFT model, log-normal AFT model, and gamma AFT model are applied to this dataset.
We select the model that best describes the data. In addition, the example illustrates that
the AFT model has a more realistic interpretation and provides more informative results
as compared to PH model. Therefore, we suggest that using the Cox PH model may not
be the optimum approach. The AFT model may provide an alternative method to t some
survival data.
One main disadvantage of using the AFT model is that the specic distribution of
survival time is unknown in many cases. Further study of this data could attempt using a
non-parametric version of the AFT model [57], which does not require the specication of
the distribution can be applied in this dataset. The results from this model could then be
compared with the standard AFT models and Cox PH models. In addition, further study
can be carried out to evaluate the e¤ects of practical cases such as large censoring.
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